BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108. [PMID: 16431890 DOI: 10.1093/ndt/gfk062] [Cited by in Crossref: 1268] [Cited by in F6Publishing: 976] [Article Influence: 84.5] [Reference Citation Analysis]
Number Citing Articles
1 Clases D, Fingerhut S, Jeibmann A, Sperling M, Doble P, Karst U. LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. Journal of Trace Elements in Medicine and Biology 2019;51:212-8. [DOI: 10.1016/j.jtemb.2018.10.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
2 Grainger RG, Thomsen HS, Morcos SK, Koh D, Roditi G. Intravascular Contrast Media for Radiology, CT and MRI. Grainger &amp Allison's Diagnostic Radiology. Elsevier; 2008. pp. 31-53. [DOI: 10.1016/b978-0-443-10163-2.50005-1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis: A serious iatrogenic disease of renal failure patients. Scandinavian Journal of Urology and Nephrology 2007;41:565-6. [DOI: 10.1080/00365590701701327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
4 Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol 2018;84:2522-34. [PMID: 30032482 DOI: 10.1111/bcp.13718] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
5 Varga J, Denton CP. Systemic Sclerosis and the Scleroderma-Spectrum Disorders. Kelley's Textbook of Rheumatology. Elsevier; 2009. pp. 1311-51. [DOI: 10.1016/b978-1-4160-3285-4.10077-4] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 Nezafat R. Native T1 Mapping for Myocardial Infarction: Time to Throw Out the Gadolinium? JACC Cardiovasc Imaging 2015;8:1031-3. [PMID: 26381765 DOI: 10.1016/j.jcmg.2015.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Rossi C, Boss A, Artunc F, Yildiz S, Martirosian P, Dittmann H, Claussen CD, Heyne N, Schick F, Schlemmer H. Comprehensive Assessment of Renal Function and Vessel Morphology in Potential Living Kidney Donors: An MRI-Based Approach. Investigative Radiology 2009;44:705-11. [DOI: 10.1097/rli.0b013e3181b35a70] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
8 Kuźnik N, Szafraniec-gorol G, Oczek L, Grucela A, Jewuła P, Kuźnik A, Zassowski P, Domagala W. A study on the synthesis and properties of substituted EHBG-Fe(III) complexes as potential MRI contrast agents. Journal of Organometallic Chemistry 2014;769:100-5. [DOI: 10.1016/j.jorganchem.2014.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S, Factor C, Le Greneur S, Medina C, Bourrinet P, Raynal I, Idée JM, Corot C. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol 2019;54:475-84. [PMID: 30973459 DOI: 10.1097/RLI.0000000000000563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
10 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
11 Attenberger UI, Michaely HJ, Wintersperger BJ, Sourbron SP, Lodemann KP, Reiser MF, Schoenberg SO. Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T. Eur Radiol 2008;18:1260-8. [PMID: 18278504 DOI: 10.1007/s00330-008-0873-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
12 Bonnet CS, Tóth É. Metal-based environment-sensitive MRI contrast agents. Curr Opin Chem Biol 2021;61:154-69. [PMID: 33706246 DOI: 10.1016/j.cbpa.2021.01.013] [Reference Citation Analysis]
13 Gossner J. Is Nephrogenic Systemic Fibrosis Linked to the Introduction of Contrast-enhanced MR Angiography? Radiology 2009;251:612-3. [DOI: 10.1148/radiol.2512082246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Bashir MR. Magnetic Resonance Contrast Agents for Liver Imaging. Magnetic Resonance Imaging Clinics of North America 2014;22:283-93. [DOI: 10.1016/j.mric.2014.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
15 Schreyer A, Debl K, Herfarth H. Internistische Indikation zur Magnetresonanztomographie: Wann brauchen wir sie wirklich? Internist 2010;51:451-62. [DOI: 10.1007/s00108-009-2452-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Raczeck P, Fries P, Bücker A, Schneider G. [Gadolinium deposition-"gadolinium deposition disease"]. Radiologe 2019;59:435-43. [PMID: 30963195 DOI: 10.1007/s00117-019-0522-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Farrell TP, Adams NC, Looby S. Neuroimaging of central diabetes insipidus. Handb Clin Neurol 2021;181:207-37. [PMID: 34238459 DOI: 10.1016/B978-0-12-820683-6.00016-6] [Reference Citation Analysis]
18 Canjels LPW, Jansen JFA, van den Kerkhof M, Alers RJ, Poser BA, Wiggins CJ, Schiffer VMMM, van de Ven V, Rouhl RPW, Palm WM, van Oostenbrugge RJ, Aldenkamp AP, Ghossein-Doha C, Spaanderman MEA, Backes WH. 7T dynamic contrast-enhanced MRI for the detection of subtle blood-brain barrier leakage. J Neuroimaging 2021;31:902-11. [PMID: 34161640 DOI: 10.1111/jon.12894] [Reference Citation Analysis]
19 Rowe MD, Chang CC, Thamm DH, Kraft SL, Harmon JF Jr, Vogt AP, Sumerlin BS, Boyes SG. Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. Langmuir 2009;25:9487-99. [PMID: 19422256 DOI: 10.1021/la900730b] [Cited by in Crossref: 100] [Cited by in F6Publishing: 77] [Article Influence: 8.3] [Reference Citation Analysis]
20 Thomsen HS. Nephrogenic Systemic Fibrosis: NEPHROGENIC SYSTEMIC FIBROSIS. Imaging Decisions MRI 2008;11:13-8. [DOI: 10.1111/j.1617-0830.2007.00110.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Anderson MA, Harrington SG, Kozak BM, Gee MS. Strategies to Reduce the Use of Gadolinium-Based Contrast Agents for Abdominal MRI in Children. American Journal of Roentgenology 2020;214:1054-64. [DOI: 10.2214/ajr.19.22232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
22 Ersoy H, Rybicki FJ. MR angiography of the lower extremities. AJR Am J Roentgenol 2008;190:1675-84. [PMID: 18492924 DOI: 10.2214/AJR.07.2223] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
23 Carkaci S, Santiago L, Adrada BE, Whitman GJ. Screening for Breast Cancer with Sonography. Seminars in Roentgenology 2011;46:285-91. [DOI: 10.1053/j.ro.2011.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
24 Liu G, Swierczewska M, Niu G, Zhang X, Chen X. Molecular imaging of cell-based cancer immunotherapy. Mol Biosyst 2011;7:993-1003. [PMID: 21308113 DOI: 10.1039/c0mb00198h] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
25 Leyendecker JR, Childs DD. Kidneys and MR Urography. Magnetic Resonance Imaging Clinics of North America 2007;15:373-82. [DOI: 10.1016/j.mric.2007.06.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
26 Cavallo AU, Koktzoglou I, Edelman RR, Gilkeson R, Mihai G, Shin T, Rajagopalan S. Noncontrast Magnetic Resonance Angiography for the Diagnosis of Peripheral Vascular Disease. Circ: Cardiovascular Imaging 2019;12. [DOI: 10.1161/circimaging.118.008844] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
27 Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 2010;55:1040-9. [PMID: 20430497 DOI: 10.1053/j.ajkd.2010.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Avedano S, Botta M, Haigh JS, Longo DL, Woods M. Coupling fast water exchange to slow molecular tumbling in Gd3+ chelates: why faster is not always better. Inorg Chem 2013;52:8436-50. [PMID: 23841587 DOI: 10.1021/ic400308a] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
29 Vivier P, Dacher J. Contrast Medium Issues in MR Urography. Academic Radiology 2009;16:772. [DOI: 10.1016/j.acra.2009.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Lima XT, Alora-palli MB, Kimball AB, Kay J. Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care Res 2013;65:637-42. [DOI: 10.1002/acr.21877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Polasek M, Caravan P. Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands. Inorg Chem 2013;52:4084-96. [PMID: 23517079 DOI: 10.1021/ic400227k] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
32 Czeyda-Pommersheim F, Martin DR, Costello JR, Kalb B. Contrast Agents for MR Imaging. Magn Reson Imaging Clin N Am 2017;25:705-11. [PMID: 28964460 DOI: 10.1016/j.mric.2017.06.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Mihai G, Simonetti OP, Thavendiranathan P. Noncontrast MRA for the diagnosis of vascular diseases. Cardiol Clin 2011;29:341-50. [PMID: 21803224 DOI: 10.1016/j.ccl.2011.04.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Feng M, Fan YZ, Ma XJ, Li JX, Yang XG. The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. Metallomics 2015;7:1103-10. [PMID: 25867453 DOI: 10.1039/c5mt00055f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Do C, Ford B, Lee DY, Tan C, Escobar P, Wagner B. Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors. Toxicol Appl Pharmacol 2019;375:32-45. [PMID: 31082427 DOI: 10.1016/j.taap.2019.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
36 Huynh K, Baghdanian AH, Baghdanian AA, Sun DS, Kolli KP, Zagoria RJ. Updated guidelines for intravenous contrast use for CT and MRI. Emerg Radiol 2020;27:115-26. [PMID: 31925592 DOI: 10.1007/s10140-020-01751-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Su P, Mao D, Liu P, Li Y, Pinho MC, Welch BG, Lu H. Multiparametric estimation of brain hemodynamics with MR fingerprinting ASL. Magn Reson Med 2017;78:1812-23. [PMID: 28019021 DOI: 10.1002/mrm.26587] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
38 Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion in Rheumatology 2006;18:614-7. [DOI: 10.1097/01.bor.0000245725.94887.8d] [Cited by in Crossref: 121] [Cited by in F6Publishing: 89] [Article Influence: 8.1] [Reference Citation Analysis]
39 Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol 2017;52:396-404. [PMID: 28125438 DOI: 10.1097/RLI.0000000000000352] [Cited by in Crossref: 141] [Cited by in F6Publishing: 44] [Article Influence: 47.0] [Reference Citation Analysis]
40 Künnemeyer J, Terborg L, Nowak S, Telgmann L, Tokmak F, Krämer BK, Günsel A, Wiesmüller GA, Waldeck J, Bremer C, Karst U. Analysis of the Contrast Agent Magnevist and Its Transmetalation Products in Blood Plasma by Capillary Electrophoresis/Electrospray Ionization Time-of-Flight Mass Spectrometry. Anal Chem 2009;81:3600-7. [DOI: 10.1021/ac8027118] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
41 Xu J, Lu X, Shi GP. Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci 2015;16:11574-608. [PMID: 26006236 DOI: 10.3390/ijms160511574] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 10.3] [Reference Citation Analysis]
42 Mytsyk Y, Borys Y, Komnatska I, Dutka I, Shatynska-Mytsyk I. Value of the diffusion-weighted MRI in the differential diagnostics of malignant and benign kidney neoplasms - our clinical experience. Pol J Radiol 2014;79:290-5. [PMID: 25202435 DOI: 10.12659/PJR.890604] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
43 Bruckman MA, Jiang K, Simpson EJ, Randolph LN, Luyt LG, Yu X, Steinmetz NF. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett 2014;14:1551-8. [PMID: 24499194 DOI: 10.1021/nl404816m] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 15.6] [Reference Citation Analysis]
44 El Habnouni S, Nottelet B, Darcos V, Porsio B, Lemaire L, Franconi F, Garric X, Coudane J. MRI-Visible Poly(ε-caprolactone) with Controlled Contrast Agent Ratios for Enhanced Visualization in Temporary Imaging Applications. Biomacromolecules 2013;14:3626-34. [DOI: 10.1021/bm400978a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
45 Bode AS, Planken RN, Merkx MA, van der Sande FM, Geerts L, Tordoir JH, Leiner T. Feasibility of non-contrast-enhanced magnetic resonance angiography for imaging upper extremity vasculature prior to vascular access creation. Eur J Vasc Endovasc Surg. 2012;43:88-94. [PMID: 22070856 DOI: 10.1016/j.ejvs.2011.09.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
46 Holtkamp H, Grabmann G, Hartinger CG. Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry: General. ELECTROPHORESIS 2016;37:959-72. [DOI: 10.1002/elps.201500502] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
47 Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 2014;175:113-25. [PMID: 24111526 DOI: 10.1111/cei.12211] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
48 Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010;254:47-66. [PMID: 20032142 DOI: 10.1148/radiol.09090021] [Cited by in Crossref: 575] [Cited by in F6Publishing: 459] [Article Influence: 52.3] [Reference Citation Analysis]
49 Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008;34:199-220; ix. [PMID: 18329541 DOI: 10.1016/j.rdc.2007.11.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
50 Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-75. [PMID: 18385397 DOI: 10.2215/CJN.00100108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
51 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
52 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50. [PMID: 33604544 DOI: 10.1016/j.xkme.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
53 Bennett CL, Hoque S, Olivieri N, Taylor MA, Aboulafia D, Lubaczewski C, Bennett AC, Vemula J, Schooley B, Witherspoon BJ, Godwin AC, Ray PS, Yarnold PR, Ausdenmoore HC, Fishman M, Herring G, Ventrone A, Aldaco J, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Marx R, Migliorati C, Ruggiero S, Nabhan C, Carson KR, McKoy JM, Yang YT, Schoen MW, Knopf K, Martin L, Sartor O, Rosen S, Smith WK. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine 2021;31:100693. [PMID: 33554084 DOI: 10.1016/j.eclinm.2020.100693] [Reference Citation Analysis]
54 Senpan A, Caruthers SD, Rhee I, Mauro NA, Pan D, Hu G, Scott MJ, Fuhrhop RW, Gaffney PJ, Wickline SA. Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano. 2009;3:3917-3926. [PMID: 19908850 DOI: 10.1021/nn900819y] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
55 Vlijm A, van Schuppen J, Lamers AB, Struijk DG, Krediet RT. Imaging in encapsulating peritoneal sclerosis. NDT Plus 2011;4:281-4. [PMID: 25984169 DOI: 10.1093/ndtplus/sfr068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Rasche V, Oberhuber A, Trumpp S, Bornstedt A, Orend KH, Merkle N, Rottbauer W, Hoffmann M. MRI assessment of thoracic stent grafts after emergency implantation in multi trauma patients: a feasibility study. Eur Radiol 2011;21:1397-405. [PMID: 21331596 DOI: 10.1007/s00330-011-2074-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
57 Panesar M, Yacoub R. What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis? Seminars in Dialysis 2011;24:373-4. [DOI: 10.1111/j.1525-139x.2011.00913.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Marckmann P, Skov L. Nephrogenic Systemic Fibrosis: Clinical Picture and Treatment. Radiologic Clinics of North America 2009;47:833-40. [DOI: 10.1016/j.rcl.2009.05.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
59 Lohani S, Golenbiewski J, Swami A, Halalau A. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. BMJ Case Rep 2017;2017:bcr-2017-221016. [PMID: 29025775 DOI: 10.1136/bcr-2017-221016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
60 Morcos SK, Bellin M, Thomsen HS, Almén T, Aspelin P, Heinz-peer G, Jakobsen JÅ, Liss P, Oyen R, Stacul F, van der Molen AJ, Webb JA. Reducing the risk of iodine-based and MRI contrast media administration: Recommendation for a questionnaire at the time of booking. European Journal of Radiology 2008;66:225-9. [DOI: 10.1016/j.ejrad.2008.01.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
61 Olchowy C, Cebulski K, Łasecki M, Chaber R, Olchowy A, Kałwak K, Zaleska-Dorobisz U. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review. PLoS One 2017;12:e0171704. [PMID: 28187173 DOI: 10.1371/journal.pone.0171704] [Cited by in Crossref: 109] [Cited by in F6Publishing: 79] [Article Influence: 27.3] [Reference Citation Analysis]
62 Matson ML, Wilson LJ. Nanotechnology and MRI contrast enhancement. Future Medicinal Chemistry 2010;2:491-502. [DOI: 10.4155/fmc.10.3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
63 Lanzman RS, Kröpil P, Schmitt P, Wittsack HJ, Orzechowski D, Kuhlemann J, Buchbender C, Miese FR, Antoch G, Blondin D. Nonenhanced ECG-gated time-resolved 4D steady-state free precession (SSFP) MR angiography (MRA) of cerebral arteries: comparison at 1.5T and 3T. Eur J Radiol 2012;81:e531-5. [PMID: 21726972 DOI: 10.1016/j.ejrad.2011.06.044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
64 Taouli B, Sandberg A, Stemmer A, Parikh T, Wong S, Xu J, Lee VS. Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. J Magn Reson Imaging. 2009;30:561-568. [PMID: 19711402 DOI: 10.1002/jmri.21876] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 10.1] [Reference Citation Analysis]
65 Rota E, Nallino MG, Bainotti S, Formica M. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol Int 2010;30:1389-91. [PMID: 19693506 DOI: 10.1007/s00296-009-1083-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Heydari B, Jerosch-Herold M, Kwong RY. Assessment of myocardial ischemia with cardiovascular magnetic resonance. Prog Cardiovasc Dis 2011;54:191-203. [PMID: 22014487 DOI: 10.1016/j.pcad.2011.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
67 Bolskar RD. Gadolinium Endohedral Metallofullerene-Based MRI Contrast Agents. In: Cataldo F, Da Ros T, editors. Medicinal Chemistry and Pharmacological Potential of Fullerenes and Carbon Nanotubes. Dordrecht: Springer Netherlands; 2008. pp. 157-80. [DOI: 10.1007/978-1-4020-6845-4_8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
68 Kuo PH. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol 2008;5:29-35. [PMID: 18180006 DOI: 10.1016/j.jacr.2007.08.014] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
69 Tsushima Y, Awai K, Shinoda G, Miyoshi H, Chosa M, Sunaya T, Endrikat J. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. Jpn J Radiol 2018;36:676-85. [PMID: 30232584 DOI: 10.1007/s11604-018-0778-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
70 Boyd AS, Sanyal S, Abraham JL. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. Journal of the American Academy of Dermatology 2008;59:356-8. [DOI: 10.1016/j.jaad.2008.01.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
71 Kromrey ML, Liedtke KR, Ittermann T, Langner S, Kirsch M, Weitschies W, Kühn JP. Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years. Eur Radiol 2017;27:772-7. [PMID: 27221561 DOI: 10.1007/s00330-016-4418-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
72 Beckett KR, Moriarity AK, Langer JM. Safe Use of Contrast Media: What the Radiologist Needs to Know. RadioGraphics 2015;35:1738-50. [DOI: 10.1148/rg.2015150033] [Cited by in Crossref: 120] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
73 Deloach SS, Mohler ER. Peripheral Arterial Disease: A Guide for Nephrologists. CJASN 2007;2:839-46. [DOI: 10.2215/cjn.04101206] [Cited by in Crossref: 43] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
74 Varjú C, Kumánovics G, Czirják L, Matucci-Cerinic M, Minier T. Sclerodermalike syndromes: Great imitators. Clin Dermatol 2020;38:235-49. [PMID: 32513403 DOI: 10.1016/j.clindermatol.2019.10.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
75 Rosenkranz AR, Grobner T, Mayer GJ. Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 2007;119:271-5. [DOI: 10.1007/s00508-007-0801-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
76 Penfield JG, Reilly RF. Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?: GADOLINIUM AND NEPHROGENIC SYSTEMIC FIBROSIS. Seminars in Dialysis 2011;24:480-6. [DOI: 10.1111/j.1525-139x.2011.00945.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 2008;13:235-41. [PMID: 18221255 DOI: 10.1111/j.1440-1797.2007.00912.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
78 Meng H, Grosse-Wortmann L. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. J Cardiovasc Magn Reson 2012;14:56. [PMID: 22871150 DOI: 10.1186/1532-429X-14-56] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
79 Lim RP, Hecht EM, Xu J, Babb JS, Oesingmann N, Wong S, Muhs BE, Gagne P, Lee VS. 3D nongadolinium-enhanced ECG-gated MRA of the distal lower extremities: Preliminary clinical experience. J Magn Reson Imaging 2008;28:181-9. [DOI: 10.1002/jmri.21416] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
80 Balassy C, Roberts D, Miller SF. Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies. Pediatr Radiol 2015;45:1831-41. [PMID: 26045036 DOI: 10.1007/s00247-015-3394-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
81 Silverman SG, Israel GM, Herts BR, Richie JP. Management of the Incidental Renal Mass. Radiology 2008;249:16-31. [DOI: 10.1148/radiol.2491070783] [Cited by in Crossref: 297] [Cited by in F6Publishing: 205] [Article Influence: 22.8] [Reference Citation Analysis]
82 Yodsanit N, Wang B, Zhao Y, Guo LW, Kent KC, Gong S. Recent progress on nanoparticles for targeted aneurysm treatment and imaging. Biomaterials 2021;265:120406. [PMID: 32979792 DOI: 10.1016/j.biomaterials.2020.120406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
83 Wu Y, Agarwal S, Jones CK, Webb AG, van Zijl PC, Hua J, Pillai JJ. Measurement of arteriolar blood volume in brain tumors using MRI without exogenous contrast agent administration at 7T. J Magn Reson Imaging 2016;44:1244-55. [PMID: 27028493 DOI: 10.1002/jmri.25248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
84 Elster A. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Yearbook of Diagnostic Radiology 2007;2007:182-4. [DOI: 10.1016/s0098-1672(08)70128-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Schilling K, Narayanan D, Kalinyak JE, The J, Velasquez MV, Kahn S, Saady M, Mahal R, Chrystal L. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2011;38:23-36. [PMID: 20871992 DOI: 10.1007/s00259-010-1588-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
86 Runge VM, Heverhagen JT. Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance. Invest Radiol 2018;53:381-9. [PMID: 29462023 DOI: 10.1097/RLI.0000000000000454] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
87 Heshmatzadeh Behzadi A, Prince MR. Preventing Allergic Reactions to Gadolinium-Based Contrast Agents. Topics in Magnetic Resonance Imaging 2016;25:275-9. [DOI: 10.1097/rmr.0000000000000106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
88 Cahalane AM, Kearney H, Purcell YM, Mcguigan C, Killeen RP. MRI and multiple sclerosis––the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective. Ir J Med Sci 2018;187:781-7. [DOI: 10.1007/s11845-017-1714-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015;50:416-22. [PMID: 25756684 DOI: 10.1097/RLI.0000000000000145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 7.8] [Reference Citation Analysis]
90 Michaely HJ, Attenberger UI, Kramer H, Nael K, Reiser MF, Schoenberg SO. Abdominal and Pelvic MR Angiography. Magnetic Resonance Imaging Clinics of North America 2007;15:301-14. [DOI: 10.1016/j.mric.2007.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
91 Garcia J, Liu SZ, Louie AY. Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus. Philos Trans A Math Phys Eng Sci 2017;375:20170180. [PMID: 29038383 DOI: 10.1098/rsta.2017.0180] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
92 Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88. [PMID: 18440117 DOI: 10.1016/j.tox.2008.03.012] [Cited by in Crossref: 114] [Cited by in F6Publishing: 87] [Article Influence: 8.8] [Reference Citation Analysis]
93 Anemone A, Consolino L, Longo DL. MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. Eur Radiol 2017;27:2170-9. [DOI: 10.1007/s00330-016-4552-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
94 Peak AS, Sheller A. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Ann Pharmacother. 2007;41:1481-1485. [PMID: 17684032 DOI: 10.1345/aph.1k295] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
95 Rahatli FK, Donmez FY, Kibaroglu S, Kesim C, Haberal KM, Turnaoglu H, Agildere AM. Does renal function affect gadolinium deposition in the brain? Eur J Radiol 2018;104:33-7. [PMID: 29857863 DOI: 10.1016/j.ejrad.2018.04.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
96 Samtleben W. [Nephrogenic systemic fibrosis]. Radiologe 2007;47:778-84. [PMID: 17717643 DOI: 10.1007/s00117-007-1545-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
97 Beomonte Zobel B, Quattrocchi CC, Errante Y, Grasso RF. Gadolinium-based contrast agents: did we miss something in the last 25 years? Radiol Med 2016;121:478-81. [PMID: 26706453 DOI: 10.1007/s11547-015-0614-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
98 Ferreira N, Ferreira A, Viana T, Lopes CB, Costa M, Pinto J, Soares J, Pinheiro-torres J, Henriques B, Pereira E. Assessment of marine macroalgae potential for gadolinium removal from contaminated aquatic systems. Science of The Total Environment 2020;749:141488. [DOI: 10.1016/j.scitotenv.2020.141488] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
99 Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;58:2543-2548. [PMID: 18668587 DOI: 10.1002/art.23696] [Cited by in Crossref: 116] [Cited by in F6Publishing: 89] [Article Influence: 8.9] [Reference Citation Analysis]
100 Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61:868-874. [PMID: 19836645 DOI: 10.1016/j.jaad.2009.03.040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
101 Lord ML, Mcneill FE, Gräfe JL, Noseworthy MD, Chettle DR. Self-identified gadolinium toxicity: comparison of gadolinium in bone and urine to healthy gadolinium-based contrast agent exposed volunteers. Physiol Meas 2018;39:115008. [DOI: 10.1088/1361-6579/aaedc6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
102 Li H, Hao S, Yang C, Chen G. Synthesis of Multicolor Core/Shell NaLuF₄:Yb3+/Ln3+@CaF₂ Upconversion Nanocrystals. Nanomaterials (Basel) 2017;7:E34. [PMID: 28336867 DOI: 10.3390/nano7020034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
103 Thomsen HS. Nephrogenic Systemic Fibrosis: History and Epidemiology. Radiologic Clinics of North America 2009;47:827-31. [DOI: 10.1016/j.rcl.2009.05.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
104 Saussereau E, Lacroix C, Cattaneo A, Mahieu L, Goulle J. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Science International 2008;176:54-7. [DOI: 10.1016/j.forsciint.2007.06.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
105 Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30. [PMID: 17109993 DOI: 10.1016/j.jaad.2006.10.048] [Cited by in Crossref: 294] [Cited by in F6Publishing: 238] [Article Influence: 19.6] [Reference Citation Analysis]
106 Offerman EJ, Koktzoglou I, Glielmi C, Sen A, Edelman RR. Prospective self-gated nonenhanced magnetic resonance angiography of the peripheral arteries. Magn Reson Med 2013;69:158-62. [PMID: 22392645 DOI: 10.1002/mrm.24240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
107 Pereira MIA, Pereira G, Monteiro CAP, Geraldes CFGC, Cabral Filho PE, Cesar CL, de Thomaz AA, Santos BS, Pereira GAL, Fontes A. Hydrophilic Quantum Dots Functionalized with Gd(III)-DO3A Monoamide Chelates as Bright and Effective T1-weighted Bimodal Nanoprobes. Sci Rep 2019;9:2341. [PMID: 30787475 DOI: 10.1038/s41598-019-38772-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
108 Takx RAP, Partovi S, Ghoshhajra BB. Imaging of atherosclerosis. Int J Cardiovasc Imaging 2016;32:5-12. [DOI: 10.1007/s10554-015-0730-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
109 Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, Petrali J, Sina B, Gaspari A, Kao G. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 2010;37:204-10. [PMID: 19341434 DOI: 10.1111/j.1600-0560.2009.01301.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
110 Taupitz M, Stolzenburg N, Ebert M, Schnorr J, Hauptmann R, Kratz H, Hamm B, Wagner S. Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd³⁺ to the glycosaminoglycan heparin. Contrast Media Mol Imaging 2013;8:108-16. [PMID: 23281283 DOI: 10.1002/cmmi.1500] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
111 Maravilla KR, San-Juan D, Kim SJ, Elizondo-Riojas G, Fink JR, Escobar W, Bag A, Roberts DR, Hao J, Pitrou C, Tsiouris AJ, Herskovits E, Fiebach JB. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). AJNR Am J Neuroradiol 2017;38:1681-8. [PMID: 28663267 DOI: 10.3174/ajnr.A5316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
112 Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA. 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging 2013;29:1085-94. [PMID: 23515949 DOI: 10.1007/s10554-013-0192-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
113 Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Idée JM, Ballet S, Corot C. T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. Invest Radiol 2015;50:473-80. [PMID: 26107651 DOI: 10.1097/RLI.0000000000000181] [Cited by in Crossref: 183] [Cited by in F6Publishing: 68] [Article Influence: 36.6] [Reference Citation Analysis]
114 Michaely H, Thomsen H, Reiser M, Schoenberg S. Nephrogene systemische Fibrose (NSF) – Implikationen für die Radiologie. Radiologe 2007;47:785-93. [DOI: 10.1007/s00117-007-1537-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
115 Leiner T, Herborn CU, Goyen M. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 2007;17:1921-3. [PMID: 17458550 DOI: 10.1007/s00330-007-0663-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
116 Bray BD, Boyd J, Daly C, Doyle A, Donaldson K, Fox JG, Innes A, Khan I, Mackinnon B, Peel RK, Shilliday I, Simpson K, Stewart GA, Traynor JP, Metcalfe W; Scottish Renal Registry (SRR). How safe is renal replacement therapy? A national study of mortality and adverse events contributing to the death of renal replacement therapy recipients. Nephrol Dial Transplant 2014;29:681-7. [PMID: 24068777 DOI: 10.1093/ndt/gft197] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
117 Pereto C, Coynel A, Lerat-hardy A, Gourves P, Schäfer J, Baudrimont M. Corbicula fluminea: A sentinel species for urban Rare Earth Element origin. Science of The Total Environment 2020;732:138552. [DOI: 10.1016/j.scitotenv.2020.138552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
118 Lanzman RS, Voiculescu A, Walther C, Ringelstein A, Bi X, Schmitt P, Freitag SM, Won S, Scherer A, Blondin D. ECG-gated nonenhanced 3D steady-state free precession MR angiography in assessment of transplant renal arteries: comparison with DSA. Radiology. 2009;252:914-921. [PMID: 19635833 DOI: 10.1148/radiol.2531082260] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
119 Clough TJ, Baxan N, Coakley EJ, Rivas C, Zhao L, Leclerc I, Martinez-Sanchez A, Rutter GA, Long NJ. Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas. Dalton Trans 2020;49:4732-40. [PMID: 32207493 DOI: 10.1039/d0dt00332h] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
120 Yildiz S, Cece H, Kaya I, Celik H, Taskin A, Aksoy N, Kocyigit A, Eren MA. Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level. Clin Biochem 2011;44:975-9. [PMID: 21620817 DOI: 10.1016/j.clinbiochem.2011.05.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
121 Rofsky NM. Nephrogenic systemic fibrosis: considerations for the cardiologist. JACC Cardiovasc Imaging 2008;1:457-9. [PMID: 19356467 DOI: 10.1016/j.jcmg.2008.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Engelhorn T, Doerfler A. High-molar contrast agents for CNS application: HIGH-MOLAR CONTRAST AGENTS FOR CNS APPLICATION. Imaging Decisions MRI 2008;11:26-32. [DOI: 10.1111/j.1617-0830.2007.00107.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
123 Cerwinka WH, Damien Grattan-Smith J, Kirsch AJ. Magnetic resonance urography in pediatric urology. J Pediatr Urol 2008;4:74-82; quiz 82-3. [PMID: 18631897 DOI: 10.1016/j.jpurol.2007.08.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
124 Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362. [PMID: 16885403 DOI: 10.1681/asn.2006060601] [Cited by in Crossref: 988] [Cited by in F6Publishing: 232] [Article Influence: 65.9] [Reference Citation Analysis]
125 He JQ, Iv M, Li G, Zhang M, Hayden Gephart M. Noncontrast T2-Weighted Magnetic Resonance Imaging Sequences for Long-Term Monitoring of Asymptomatic Convexity Meningiomas. World Neurosurgery 2020;135:e100-5. [DOI: 10.1016/j.wneu.2019.11.051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
126 Endre ZH. Nephrogenic systemic fibrosis: is any contrast safe in renal failure? Internal Medicine Journal 2007;37:429-31. [DOI: 10.1111/j.1445-5994.2007.01401.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
127 Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6:553-558. [PMID: 26253982 DOI: 10.1007/s13244-015-0420-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 80] [Article Influence: 18.5] [Reference Citation Analysis]
128 Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG, Froelich JW, Gilk T, Gimbel JR, Gosbee J, Kuhni-kaminski E, Lester JW, Nyenhuis J, Parag Y, Schaefer DJ, Sebek-scoumis EA, Weinreb J, Zaremba LA, Wilcox P, Lucey L, Sass N. ACR Guidance Document for Safe MR Practices: 2007. American Journal of Roentgenology 2007;188:1447-74. [DOI: 10.2214/ajr.06.1616] [Cited by in Crossref: 523] [Cited by in F6Publishing: 107] [Article Influence: 37.4] [Reference Citation Analysis]
129 Garovic VD, Achauer MA, Kittner T, Horák D, Sheng R, Stanson AW. Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: Results of a phase III multicenter trial. J Magn Reson Imaging 2010;31:390-7. [DOI: 10.1002/jmri.22032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
130 Lam A, Perchyonok Y, Ranatunga D, Lukies MW, Richmond D, Hornsey EK, Mccoll B, Heidrich J, Ko P, Spelman T, Chuen J, Edelman RR, Lim RP. Accuracy of non‐contrast quiescent‐interval single‐shot and quiescent‐interval single‐shot arterial spin‐labelled magnetic resonance angiography in assessment of peripheral arterial disease in a diabetic population. J Med Imaging Radiat Oncol 2020;64:35-43. [DOI: 10.1111/1754-9485.12987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
131 Wang ZJ, Nikolaidis P, Khatri G, Dogra VS, Ganeshan D, Goldfarb S, Gore JL, Gupta RT, Hartman RP, Heilbrun ME, Lyshchik A, Purysko AS, Savage SJ, Smith AD, Wolfman DJ, Wong-you-cheong JJ, Lockhart ME. ACR Appropriateness Criteria® Indeterminate Renal Mass. Journal of the American College of Radiology 2020;17:S415-28. [DOI: 10.1016/j.jacr.2020.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
132 Potthast S, Maki JH. Non–Contrast-Enhanced MR Imaging of the Renal Arteries. Magnetic Resonance Imaging Clinics of North America 2008;16:573-84. [DOI: 10.1016/j.mric.2008.07.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
133 Gibbons RJ, Araoz PA, Williamson EE. The year in cardiac imaging. J Am Coll Cardiol 2009;53:54-70. [PMID: 19118725 DOI: 10.1016/j.jacc.2008.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
134 Park BK, Kim CK, Kim EY. Differentiation of Bosniak categories IIF and III cystic masses: what radiologists should know. J Comput Assist Tomogr 2010;34:847-54. [PMID: 21084899 DOI: 10.1097/RCT.0b013e3181ee9e02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Amin R, Darrah T, Wang H, Amin S. Editor's Highlight: In Utero Exposure to Gadolinium and Adverse Neonatal Outcomes in Premature Infants. Toxicol Sci 2017;156:520-6. [PMID: 28201627 DOI: 10.1093/toxsci/kfx013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
136 Davison R, Mead P. Nephrogenic systemic fibrosis (NSF): the role of tamoxifen. NDT Plus 2010;3:505. [PMID: 25984072 DOI: 10.1093/ndtplus/sfq111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Ichihashi S, Marugami N, Tanaka T, Iwakoshi S, Kurumatani N, Kitano S, Nogi A, Kichikawa K. Preliminary experience with superparamagnetic iron oxide-enhanced dynamic magnetic resonance imaging and comparison with contrast-enhanced computed tomography in endoleak detection after endovascular aneurysm repair. Journal of Vascular Surgery 2013;58:66-72. [DOI: 10.1016/j.jvs.2012.12.061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
138 Pallares RM, Faulkner D, An DD, Hébert S, Loguinov A, Proctor M, Villalobos JA, Bjornstad KA, Rosen CJ, Vulpe C, Abergel RJ. Genome-wide toxicogenomic study of the lanthanides sheds light on the selective toxicity mechanisms associated with critical materials. Proc Natl Acad Sci U S A 2021;118:e2025952118. [PMID: 33903247 DOI: 10.1073/pnas.2025952118] [Reference Citation Analysis]
139 Ogura A, Maeda F, Yahata S, Koyama D, Tsunoda F, Hayashi N, Motegi S, Yamamura K. Slow component apparent diffusion coefficient for prostate cancer: Comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging. Magnetic Resonance Imaging 2019;58:14-7. [DOI: 10.1016/j.mri.2019.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
140 Morita S, Masukawa A, Suzuki K, Hirata M, Kojima S, Ueno E. Unenhanced MR Angiography: Techniques and Clinical Applications in Patients with Chronic Kidney Disease. RadioGraphics 2011;31:E13-33. [DOI: 10.1148/rg.312105075] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
141 Perazella MA. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol 2008;3:649-51. [PMID: 18385396 DOI: 10.2215/CJN.00670208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
142 Halvorsen RA. Which study when? Iodinated contrast-enhanced CT versus gadolinium-enhanced MR imaging. Radiology 2008;249:9-15. [PMID: 18796664 DOI: 10.1148/radiol.2491080593] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
143 Chewning RH, Murphy KJ. Gadolinium-based Contrast Media and the Development of Nephrogenic Systemic Fibrosis in Patients with Renal Insufficiency. Journal of Vascular and Interventional Radiology 2007;18:331-3. [DOI: 10.1016/j.jvir.2007.01.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
144 Bauman G, Bieri O. Matrix pencil decomposition of time-resolved proton MRI for robust and improved assessment of pulmonary ventilation and perfusion. Magn Reson Med. 2017;77:336-342. [PMID: 26757102 DOI: 10.1002/mrm.26096] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
145 Chow DS, Bahrami S, Raman SS, Rotchel S, Sayre JW, Busuttil RW, Lu DS. Risk of nephrogenic systemic fibrosis in liver transplantation patients. AJR Am J Roentgenol. 2011;197:658-662. [PMID: 21862808 DOI: 10.2214/ajr.10.5976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
146 Lanzman RS, Kröpil P, Schmitt P, Freitag SM, Ringelstein A, Wittsack HJ, Blondin D. Nonenhanced free-breathing ECG-gated steady-state free precession 3D MR angiography of the renal arteries: comparison between 1.5 T and 3 T. AJR Am J Roentgenol 2010;194:794-8. [PMID: 20173162 DOI: 10.2214/AJR.09.2814] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
147 Nacif MS, Arai AE, Lima JA, Bluemke DA. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 2012;14:18. [PMID: 22376193 DOI: 10.1186/1532-429X-14-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
148 Madke B, Khopkar U. Nephrogenic systemic fibrosis. Indian Dermatol Online J 2011;2:51-6. [PMID: 23130224 DOI: 10.4103/2229-5178.85990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
149 Elias Junior J, Santos ACD, Koenigkam-santos M, Nogueira-barbosa MH, Muglia VF. Complicações do uso intravenoso de agentes de contraste à base de gadolínio para ressonância magnética. Radiol Bras 2008;41:263-7. [DOI: 10.1590/s0100-39842008000400013] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
150 Pallares RM, An DD, Tewari P, Wang ET, Abergel RJ. Rapid Detection of Gadolinium-Based Contrast Agents in Urine with a Chelated Europium Luminescent Probe. ACS Sens 2020;5:1281-6. [DOI: 10.1021/acssensors.0c00615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
151 Le Fur M, Rotile NJ, Correcher C, Clavijo Jordan V, Ross AW, Catana C, Caravan P. Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents. Angew Chem Int Ed Engl 2020;59:1474-8. [PMID: 31750991 DOI: 10.1002/anie.201911858] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
152 Robic C, Catoen S, De Goltstein MC, Idée JM, Port M. The role of phosphate on Omniscan(®) dechelation: an in vitro relaxivity study at pH 7. Biometals 2011;24:759-68. [PMID: 21390525 DOI: 10.1007/s10534-011-9422-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
153 Newport JP, Dusseault BN, Butler C, Pais VM. Gadolinium-Enhanced Computed Tomography Cystogram to Diagnose Bladder Augment Rupture in Patients with Iodine Sensitivity. Urology 2008;71:984.e9-984.e11. [DOI: 10.1016/j.urology.2007.11.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
154 Nasir A. Nanotechnology and dermatology: Part II—risks of nanotechnology. Clinics in Dermatology 2010;28:581-8. [DOI: 10.1016/j.clindermatol.2009.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
155 Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ. Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem 2014;19:259-70. [PMID: 24366655 DOI: 10.1007/s00775-013-1076-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
156 Okayama S, Matsui M, Somekawa S, Iwano M, Saito Y. Non-contrast MRI for the evaluation of hydronephrotic and dysfunctioning kidney secondary to testicular cancer. Ren Fail 2009;31:153-8. [PMID: 19212914 DOI: 10.1080/08860220802595914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
157 Horváth A, Varallyay CG, Schwartz D, Toth GB, Netto JP, Barajas R, Várallyay P, Szidonya L, Firkins J, Youngers E, Fu R, Ambady P, Bogner P, Neuwelt EA. Quantitative comparison of delayed ferumoxytol T1 enhancement with immediate gadoteridol enhancement in high grade gliomas. Magn Reson Med 2018;80:224-30. [PMID: 29205477 DOI: 10.1002/mrm.27028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
158 Offerman EJ, Hodnett PA, Edelman RR, Koktzoglou I. Nonenhanced methods for lower-extremity MRA: a phantom study examining the effects of stenosis and pathologic flow waveforms at 1.5T. J Magn Reson Imaging 2011;33:401-8. [PMID: 21274982 DOI: 10.1002/jmri.22457] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
159 Wang J, Salzillo T, Jiang Y, Mackeyev Y, David Fuller C, Chung C, Choi S, Hughes N, Ding Y, Yang J, Vedam S, Krishnan S. Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac. Radiother Oncol 2021;161:55-64. [PMID: 34089753 DOI: 10.1016/j.radonc.2021.05.023] [Reference Citation Analysis]
160 Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A, Di Cesare E. Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med 2018;123:125-34. [PMID: 28952018 DOI: 10.1007/s11547-017-0816-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
161 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
162 Pao VY, Chang S, Shoback DM, Bikle DD. Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. J Bone Miner Res 2009;24:1135-9. [PMID: 19113910 DOI: 10.1359/jbmr.081261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
163 Lyapustina T, Goldfine C, Rhyee S, Babu KM, Griswold MK. Evaluating the Patient with Reported Gadolinium-Associated Illness. J Med Toxicol 2019;15:36-44. [PMID: 30499040 DOI: 10.1007/s13181-018-0689-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
164 Hope TA, Doherty A, Fu Y, Aslam R, Qayyum A, Brasch RC. Gadolinium accumulation and fibrosis in the liver after administration of gadoxetate disodium in a rat model of active hepatic fibrosis. Radiology 2012;264:423-7. [PMID: 22570507 DOI: 10.1148/radiol.12112453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
165 Sadat U, Li ZY, Graves MJ, Tang TY, Gillard JH. Noninvasive imaging of atheromatous carotid plaques. Nat Clin Pract Cardiovasc Med 2009;6:200-9. [PMID: 19234500 DOI: 10.1038/ncpcardio1455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
166 Hua J, Brandt AS, Lee S, Blair NIS, Wu Y, Lui S, Patel J, Faria AV, Lim IAL, Unschuld PG, Pekar JJ, van Zijl PCM, Ross CA, Margolis RL. Abnormal Grey Matter Arteriolar Cerebral Blood Volume in Schizophrenia Measured With 3D Inflow-Based Vascular-Space-Occupancy MRI at 7T. Schizophr Bull 2017;43:620-32. [PMID: 27539951 DOI: 10.1093/schbul/sbw109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
167 Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World J Gastroenterol. 2016;22:89-102. [PMID: 26755862 DOI: 10.3748/wjg.v22.i1.89] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
168 Shahrouki P, Moriarty JM, Khan SN, Bista B, Kee ST, DeRubertis BG, Yoshida T, Nguyen KL, Finn JP. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion. J Cardiovasc Magn Reson 2019;21:17. [PMID: 30853026 DOI: 10.1186/s12968-019-0528-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
169 Wang ST, Hua ZX, Fan DX, Zhang X, Ren K. Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model. Biomed Res Int 2019;2019:3901907. [PMID: 31192255 DOI: 10.1155/2019/3901907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
170 Bahrami S, Raman SS, Sauk S, Salehmoghaddam S, Villablanca JP, Finn JP, Lu DS. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. J Comput Assist Tomogr 2009;33:819-23. [PMID: 19940643 DOI: 10.1097/RCT.0b013e31819d68ed] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
171 Bauman G, Pusterla O, Bieri O. Ultra-fast Steady-State Free Precession Pulse Sequence for Fourier Decomposition Pulmonary MRI: Ultra-fast SSFP for FD MRI. Magn Reson Med 2016;75:1647-53. [DOI: 10.1002/mrm.25697] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
172 Kim HK, Lee GH, Chang Y. Gadolinium as an MRI contrast agent. Future Med Chem 2018;10:639-61. [PMID: 29412006 DOI: 10.4155/fmc-2017-0215] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
173 Tsagalis G, Psimenou E, Laggouranis A. Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis. Int J Artif Organs 2008;31:913-4. [DOI: 10.1177/039139880803101009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
174 Du Y, Liang X, Li Y, Sun T, Xue H, Jin Z, Tian J. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. Cancer Letters 2018;414:230-8. [DOI: 10.1016/j.canlet.2017.11.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
175 Schäd SG, Heitland P, Kühn-velten WN, Gross GE, Jonas L. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure: Gadolinium in nephrogenic fibrosis. J Cutan Pathol 2013;40:935-44. [DOI: 10.1111/cup.12214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
176 Zhen Z, Xie J. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging. Theranostics 2012;2:45-54. [PMID: 22272218 DOI: 10.7150/thno.3448] [Cited by in Crossref: 88] [Cited by in F6Publishing: 72] [Article Influence: 9.8] [Reference Citation Analysis]
177 Igreja ACDSM, Mesquita KDC, Cowper SE, Costa IMC. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012;87:597-607. [DOI: 10.1590/s0365-05962012000400013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
178 Thomsen HS, Morcos SK. Nephrogenic Systemic Fibrosis and Nonionic Linear Chelates. American Journal of Roentgenology 2007;188:W580-W580. [DOI: 10.2214/ajr.06.1651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
179 Silberzweig JI, Chung M. Removal of gadolinium by dialysis: review of different strategies and techniques. J Magn Reson Imaging 2009;30:1347-9. [PMID: 19937933 DOI: 10.1002/jmri.21981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
180 Wong G, Lee E, Irwin M. Contrast induced nephropathy in vascular surgery. British Journal of Anaesthesia 2016;117:ii63-73. [DOI: 10.1093/bja/aew213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
181 Poff JA, Hecht EM, Ramchandani P. Renal Imaging in Patients with Renal Impairment. Curr Urol Rep 2011;12:24-33. [DOI: 10.1007/s11934-010-0158-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
182 Orenstein SB, Marks JM, Hardacre JM. Technical Aspects of Bile Duct Evaluation and Exploration. Surgical Clinics of North America 2014;94:281-96. [DOI: 10.1016/j.suc.2013.12.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
183 Tweedle MF. Science to Practice: Will Gadolinium Chelates Be Replaced by Iron Chelates in MR Imaging? Radiology 2018;286:409-11. [PMID: 29356647 DOI: 10.1148/radiol.2017172305] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
184 Gale EM, Caravan P, Rao AG, Mcdonald RJ, Winfeld M, Fleck RJ, Gee MS. Gadolinium-based contrast agents in pediatric magnetic resonance imaging. Pediatr Radiol 2017;47:507-21. [DOI: 10.1007/s00247-017-3806-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
185 Chien CC, Wang HY, Wang JJ, Kan WC, Chien TW, Lin CY, Su SB. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment. Ren Fail 2011;33:758-64. [PMID: 21777176 DOI: 10.3109/0886022X.2011.599911] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
186 Hoda RS, Sanyal S, Abraham JL, Everett JM, Hundemer GL, Yee E, Lauwers GY, Tolkoff-Rubin N, Misdraji J. Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. Histopathology. 2017;70:1072-1078. [PMID: 28134986 DOI: 10.1111/his.13178] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
187 Siedek F, Muehe AM, Theruvath AJ, Avedian R, Pribnow A, Spunt SL, Liang T, Farrell C, Daldrup-Link HE. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. Eur Radiol 2020;30:1790-803. [PMID: 31844962 DOI: 10.1007/s00330-019-06569-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
188 Martino C, Chiarelli R, Bosco L, Roccheri MC. Induction of skeletal abnormalities and autophagy in Paracentrotus lividus sea urchin embryos exposed to gadolinium. Marine Environmental Research 2017;130:12-20. [DOI: 10.1016/j.marenvres.2017.07.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
189 Pasumarthi S, Tamir JI, Christensen S, Zaharchuk G, Zhang T, Gong E. A generic deep learning model for reduced gadolinium dose in contrast-enhanced brain MRI. Magn Reson Med 2021;86:1687-700. [PMID: 33914965 DOI: 10.1002/mrm.28808] [Reference Citation Analysis]
190 Zhang JL, Rusinek H, Bokacheva L, Lerman LO, Chen Q, Prince C, Oesingmann N, Song T, Lee VS. Functional assessment of the kidney from magnetic resonance and computed tomography renography: impulse retention approach to a multicompartment model. Magn Reson Med 2008;59:278-88. [PMID: 18228576 DOI: 10.1002/mrm.21489] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
191 Zhao X, Underhill HR, Yuan C, Oikawa M, Dong L, Ota H, Hatsukami TS, Wang Q, Ma L, Cai J. Minimization of MR contrast weightings for the comprehensive evaluation of carotid atherosclerotic disease. Invest Radiol 2010;45:36-41. [PMID: 19996759 DOI: 10.1097/RLI.0b013e3181beada7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
192 Saxena SK, Sharma M, Patel M, Oreopoulos D. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol 2008;40:715-24. [PMID: 18418727 DOI: 10.1007/s11255-008-9361-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
193 Waikhom R, Taraphder A. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56:54-58. [PMID: 21572794 DOI: 10.4103/0019-5154.77554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
194 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
195 Weinstein S, Rosen M. Breast MR imaging: current indications and advanced imaging techniques. Radiol Clin North Am 2010;48:1013-42. [PMID: 20868898 DOI: 10.1016/j.rcl.2010.06.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
196 Byars JA, Rosenberg EI. Diabetic myonecrosis in an orthotopic heart transplant recipient. J Heart Lung Transplant 2007;26:549-52. [PMID: 17449428 DOI: 10.1016/j.healun.2007.01.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
197 Kimura A, Jo JI, Yoshida F, Hong Z, Tabata Y, Sumiyoshi A, Taguchi M, Aoki I. Ultra-small size gelatin nanogel as a blood brain barrier impermeable contrast agent for magnetic resonance imaging. Acta Biomater 2021;125:290-9. [PMID: 33601066 DOI: 10.1016/j.actbio.2021.02.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Marzella L, Blank M, Gelperin K, Johann-liang R. Safety risks with gadolinium-based contrast agents. J Magn Reson Imaging 2007;26:816-816. [DOI: 10.1002/jmri.21021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
199 Ghiassi KB, Olmstead MM, Balch AL. Gadolinium-containing endohedral fullerenes: structures and function as magnetic resonance imaging (MRI) agents. Dalton Trans 2014;43:7346-58. [PMID: 24522668 DOI: 10.1039/c3dt53517g] [Cited by in Crossref: 61] [Cited by in F6Publishing: 8] [Article Influence: 10.2] [Reference Citation Analysis]
200 Lim RP, Fan Z, Chatterji M, Baadh A, Atanasova IP, Storey P, Kim DC, Kim S, Hodnett PA, Ahmad A, Stoffel DR, Babb JS, Adelman MA, Xu J, Li D, Lee VS. Comparison of nonenhanced MR angiographic subtraction techniques for infragenual arteries at 1.5 T: a preliminary study. Radiology 2013;267:293-304. [PMID: 23297320 DOI: 10.1148/radiol.12120859] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
201 Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Ordovas KG, Saloner D. Vascular Imaging With Ferumoxytol as a Contrast Agent. AJR Am J Roentgenol 2015;205:W366-73. [PMID: 26102308 DOI: 10.2214/AJR.15.14534] [Cited by in Crossref: 73] [Cited by in F6Publishing: 31] [Article Influence: 12.2] [Reference Citation Analysis]
202 Smeraldo A, Netti PA, Torino E. New Strategies in the Design of Paramagnetic CAs. Contrast Media Mol Imaging 2020;2020:4327479. [PMID: 33071681 DOI: 10.1155/2020/4327479] [Reference Citation Analysis]
203 Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-parker S, Martin DR. Nephrogenic systemic fibrosis: Center case review. J Magn Reson Imaging 2007;26:1198-203. [DOI: 10.1002/jmri.21136] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
204 Caufield JH, Zhou Y, Garlid AO, Setty SP, Liem DA, Cao Q, Lee JM, Murali S, Spendlove S, Wang W, Zhang L, Sun Y, Bui A, Hermjakob H, Watson KE, Ping P. A reference set of curated biomedical data and metadata from clinical case reports. Sci Data 2018;5:180258. [PMID: 30457569 DOI: 10.1038/sdata.2018.258] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
205 Mallio CA, Quattrocchi CC, Rovira À, Parizel PM. Gadolinium Deposition Safety: Seeking the Patient's Perspective. AJNR Am J Neuroradiol 2020;41:944-6. [PMID: 32381539 DOI: 10.3174/ajnr.A6586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
206 Lee VS. MRI: From science to society. J Magn Reson Imaging 2013;37:753-60. [DOI: 10.1002/jmri.24044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
207 Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011;26:1099-101. [PMID: 21079195 DOI: 10.1093/ndt/gfq693] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
208 Malikova H. Nephrogenic systemic fibrosis: the end of the story? Quant Imaging Med Surg 2019;9:1470-4. [PMID: 31559176 DOI: 10.21037/qims.2019.07.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
209 Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. [PMID: 18501784 DOI: 10.1053/j.ajkd.2007.12.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
210 Ranjan S, Jayakumar MKG, Zhang Y. Luminescent lanthanide nanomaterials: an emerging tool for theranostic applications. Nanomedicine 2015;10:1477-91. [DOI: 10.2217/nnm.14.229] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
211 Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654-668. [PMID: 18033225 DOI: 10.1038/ncpneph0660] [Cited by in Crossref: 241] [Cited by in F6Publishing: 195] [Article Influence: 18.5] [Reference Citation Analysis]
212 Chang EH. An Introduction to Contrast-Enhanced Ultrasound for Nephrologists. Nephron 2018;138:176-85. [PMID: 29131073 DOI: 10.1159/000484635] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
213 Shen L, Yang A, Yao P, Sun X, Chen C, Mo C, Shi L, Chen Y, Liu Q. Gadolinium promoted proliferation in mouse embryo fibroblast NIH3T3 cells through Rac and PI3K/Akt signaling pathways. Biometals 2014;27:753-62. [DOI: 10.1007/s10534-014-9769-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
214 Krestan C. [Contrast media - Guidelines for practical use]. Radiologe 2019;59:444-53. [PMID: 31025046 DOI: 10.1007/s00117-019-0523-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid. Journal of the American Academy of Dermatology 2011;64:741-7. [DOI: 10.1016/j.jaad.2010.05.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
216 Wyskocka-Gajda M, Przypis Ł, Olesiejuk M, Krawczyk T, Kuźnik A, Nawara K, Minoshima M, Sugihara F, Kikuchi K, Kuźnik N. A step towards gadolinium-free bioresponsive MRI contrast agent. Eur J Med Chem 2021;211:113086. [PMID: 33348236 DOI: 10.1016/j.ejmech.2020.113086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
217 Misra S, Sturludottir M, Mathew V, Bjarnason H, Mckusick M, Iyer VK. Treatment of Complex Stenoses Involving Renal Artery Bifurcations with Use of Drug-eluting Stents. Journal of Vascular and Interventional Radiology 2008;19:272-8. [DOI: 10.1016/j.jvir.2007.10.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
218 McCray CJ, Mayes MD. Update on systemic sclerosis. Curr Allergy Asthma Rep 2015;15:25. [PMID: 26139334 DOI: 10.1007/s11882-015-0526-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
219 Jensen UR, Liu JR, Eschenfelder C, Meyne J, Zhao Y, Deuschl G, Jansen O, Ulmer S. The correlation between quantitative T2' and regional cerebral blood flow after acute brain ischemia in early reperfusion as demonstrated in a middle cerebral artery occlusion/reperfusion model of the rat. J Neurosci Methods 2009;178:55-8. [PMID: 19103223 DOI: 10.1016/j.jneumeth.2008.11.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
220 Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Fisher GJ, Johnson KJ, Swartz R, Varani J. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 2009;44:433-9. [PMID: 19561517 DOI: 10.1097/RLI.0b013e3181a4d7e9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
221 Carrasco Muñoz S, Calles Blanco C, Marcin J, Fernández Álvarez C, Lafuente Martínez J. Contrastes basados en gadolinio utilizados en resonancia magnética. Radiología 2014;56:21-8. [DOI: 10.1016/j.rx.2014.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
222 Shukla S, Steinmetz NF. Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015;7:708-21. [PMID: 25683790 DOI: 10.1002/wnan.1335] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
223 Pullicino R, Radon M, Biswas S, Bhojak M, Das K. A Review of the Current Evidence on Gadolinium Deposition in the Brain. Clin Neuroradiol 2018;28:159-69. [PMID: 29523896 DOI: 10.1007/s00062-018-0678-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
224 Mora GF. Systemic sclerosis: environmental factors. J Rheumatol. 2009;36:2383-2396. [PMID: 19797508 DOI: 10.3899/jrheum.090207] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
225 Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
226 Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol 2009;19:1417-24. [PMID: 19169690 DOI: 10.1007/s00330-008-1259-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
227 Ryu YJ, Choi YH, Cheon JE, Lee WJ, Park S, Park JE, Kim WS, Kim IO. Pediatric Brain: Gadolinium Deposition in Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images Is Dependent on the Type of Contrast Agent. Invest Radiol 2018;53:246-55. [PMID: 29300210 DOI: 10.1097/RLI.0000000000000436] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 14.5] [Reference Citation Analysis]
228 Karakatsani ME, Pouliopoulos AN, Liu M, Jambawalikar SR, Konofagou EE. Contrast-Free Detection of Focused Ultrasound-Induced Blood-Brain Barrier Opening Using Diffusion Tensor Imaging. IEEE Trans Biomed Eng 2021;68:2499-508. [PMID: 33360980 DOI: 10.1109/TBME.2020.3047575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
229 Renjen P, Bellah R, Hellinger JC, Darge K. Advances in Uroradiologic Imaging in Children. Radiologic Clinics of North America 2012;50:207-18. [DOI: 10.1016/j.rcl.2012.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
230 Semelka RC, Armao DM, Elias J, Huda W. Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. J Magn Reson Imaging. 2007;25:900-909. [PMID: 17457809 DOI: 10.1002/jmri.20895] [Cited by in Crossref: 152] [Cited by in F6Publishing: 105] [Article Influence: 10.9] [Reference Citation Analysis]
231 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
232 Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157. [PMID: 17267695 DOI: 10.1148/radiol.2431062144] [Cited by in Crossref: 715] [Cited by in F6Publishing: 544] [Article Influence: 51.1] [Reference Citation Analysis]
233 Said ZH, Lerakis S. The role of magnetic resonance angiography in peripheral artery disease. Current Opinion in Pharmacology 2018;39:129-33. [DOI: 10.1016/j.coph.2018.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
234 Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. European Journal of Radiology 2008;66:230-4. [DOI: 10.1016/j.ejrad.2008.02.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 161] [Article Influence: 17.2] [Reference Citation Analysis]
235 Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189:318-27. [PMID: 22649203 DOI: 10.4049/jimmunol.1103099] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
236 Deo A, Fogel M, Cowper SE. Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure. CJASN 2007;2:264-7. [DOI: 10.2215/cjn.03921106] [Cited by in Crossref: 200] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
237 Martin DR. Nephrogenic Systemic Fibrosis and Gadolinium-Enhanced Magnetic Resonance Imaging: Does a US Food and Drug Administration Alert Influence Practice Patterns in CKD? American Journal of Kidney Diseases 2010;56:427-30. [DOI: 10.1053/j.ajkd.2010.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
238 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
239 Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-8. [PMID: 18356456 DOI: 10.2214/AJR.07.2822] [Cited by in Crossref: 112] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
240 Kanal E, Patton TJ, Krefting I, Wang C. Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration. AJNR Am J Neuroradiol 2020;41:393-9. [PMID: 32115422 DOI: 10.3174/ajnr.A6448] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
241 Li X, Liao S, Hua J, Guo L, Wang D, Xiao X, Zhou J, Liu X, Tan Y, Lu L, Xu Y, Wu Y. Association of Glioma Grading With Inflow-Based Vascular-Space-Occupancy MRI: A Preliminary Study at 3T. J Magn Reson Imaging 2019;50:1817-23. [PMID: 30932289 DOI: 10.1002/jmri.26741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
242 Shibukawa S, Nishio H, Niwa T, Obara M, Miyati T, Hara T, Imai Y, Muro I. Optimized 4D time-of-flight MR angiography using saturation pulse: Optimized 4D-TOF MRA. J Magn Reson Imaging 2016;43:1320-6. [DOI: 10.1002/jmri.25118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
243 Courant T, Roullin VG, Cadiou C, Callewaert M, Andry MC, Portefaix C, Hoeffel C, de Goltstein MC, Port M, Laurent S, Elst LV, Muller R, Molinari M, Chuburu F. Hydrogels Incorporating GdDOTA: Towards Highly Efficient Dual T1/T2 MRI Contrast Agents. Angew Chem Int Ed 2012;51:9119-22. [DOI: 10.1002/anie.201203190] [Cited by in Crossref: 103] [Cited by in F6Publishing: 83] [Article Influence: 11.4] [Reference Citation Analysis]
244 Glockner JF, Takahashi N, Kawashima A, Woodrum DA, Stanley DW, Takei N, Miyoshi M, Sun W. Non-contrast renal artery MRA using an inflow inversion recovery steady state free precession technique (Inhance): Comparison with 3D contrast-enhanced MRA. J Magn Reson Imaging 2010;31:1411-8. [DOI: 10.1002/jmri.22194] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
245 Marckmann P. Nephrogenic systemic fibrosis: epidemiology update: . Current Opinion in Nephrology and Hypertension 2008;17:315-9. [DOI: 10.1097/mnh.0b013e3282f4b605] [Cited by in Crossref: 32] [Article Influence: 2.5] [Reference Citation Analysis]
246 Cocozza S, Pontillo G, Lanzillo R, Russo C, Petracca M, Di Stasi M, Paolella C, Vola EA, Criscuolo C, Moccia M, Lamberti A, Monti S, Brescia Morra V, Elefante A, Palma G, Tedeschi E, Brunetti A. MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis. Neuroradiology 2019;61:155-62. [DOI: 10.1007/s00234-018-02150-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
247 Webb JAW. Pregnancy and Lactation. In: Thomsen HS, Webb JAW, editors. Contrast Media. Berlin: Springer Berlin Heidelberg; 2009. pp. 95-101. [DOI: 10.1007/978-3-540-72784-2_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Bryson J, Reineke JW, Reineke TM. Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential? Macromolecules 2012;45:8939-52. [PMID: 23467737 DOI: 10.1021/ma301568u] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
249 Petralia G, Thoeny HC. DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging 2010;10 Spec no A:S112-23. [PMID: 20880781 DOI: 10.1102/1470-7330.2010.9030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
250 Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010;256:735-43. [PMID: 20663970 DOI: 10.1148/radiol.10091131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
251 Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J. Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol 2010;183:27-33. [PMID: 19913804 DOI: 10.1016/j.juro.2009.09.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
252 Goullé J, Cattanéo A, Saussereau E, Mahieu L, Guerbet M, Lacroix C. MRI gadolinium-based contrast agents. Radiologists beware! Annales Pharmaceutiques Françaises 2009;67:335-9. [DOI: 10.1016/j.pharma.2009.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
253 Song KD, Kim SH, Lee J, Kang KA, Kim J, Yoo H. Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis. European Journal of Radiology 2015;84:378-83. [DOI: 10.1016/j.ejrad.2014.12.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
254 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
255 Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée J, Corot C. Nephrogenic Systemic Fibrosis-Like Effects of Magnetic Resonance Imaging Contrast Agents in Rats with Adenine-Induced Renal Failure. Toxicological Sciences 2013;131:259-70. [DOI: 10.1093/toxsci/kfs274] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
256 Nielsen YW, Thomsen HS. Contrast-enhanced peripheral MRA: technique and contrast agents. Acta Radiol 2012;53:769-77. [PMID: 22843836 DOI: 10.1258/ar.2012.120008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
257 Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol. 2006;61:905-906. [PMID: 17018301 DOI: 10.1016/j.crad.2006.09.003] [Cited by in Crossref: 118] [Cited by in F6Publishing: 88] [Article Influence: 7.9] [Reference Citation Analysis]
258 Dillman JR, Davenport MS. Gadolinium retention - 5 years later…. Pediatr Radiol 2020;50:166-7. [PMID: 31975183 DOI: 10.1007/s00247-019-04540-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Zhang JL, Conlin CC, Carlston K, Xie L, Kim D, Morrell G, Morton K, Lee VS. Optimization of saturation-recovery dynamic contrast-enhanced MRI acquisition protocol: monte carlo simulation approach demonstrated with gadolinium MR renography. NMR Biomed 2016;29:969-77. [PMID: 27200499 DOI: 10.1002/nbm.3553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
260 Jalandhara N, Arora R, Batuman V. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. Clin Pharmacol Ther 2011;89:920-3. [DOI: 10.1038/clpt.2010.346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
261 Anzalone N. Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features. AJNR Am J Neuroradiol 2010;31:981-2. [PMID: 20299432 DOI: 10.3174/ajnr.A2068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
262 Wang C, Cheng D, Jalali Motlagh N, Kuellenberg EG, Wojtkiewicz GR, Schmidt SP, Stocker R, Chen JW. Highly Efficient Activatable MRI Probe to Sense Myeloperoxidase Activity. J Med Chem 2021;64:5874-85. [PMID: 33945286 DOI: 10.1021/acs.jmedchem.1c00038] [Reference Citation Analysis]
263 Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, Dame MK, Varani J. Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 2011;144:621-35. [PMID: 21484406 DOI: 10.1007/s12011-011-9041-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
264 Kim KH, Fonda JR, Lawler EV, Gagnon D, Kaufman JS. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008. Am J Kidney Dis 2010;56:458-67. [PMID: 20580477 DOI: 10.1053/j.ajkd.2010.03.027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
265 Fok JS, Smith WB. Hypersensitivity reactions to gadolinium-based contrast agents. Current Opinion in Allergy & Clinical Immunology 2017;17:241-6. [DOI: 10.1097/aci.0000000000000371] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.8] [Reference Citation Analysis]
266 Kálmán FK, Nagy V, Váradi B, Garda Z, Molnár E, Trencsényi G, Kiss J, Même S, Même W, Tóth É, Tircsó G. Mn(II)-Based MRI Contrast Agent Candidate for Vascular Imaging. J Med Chem 2020;63:6057-65. [DOI: 10.1021/acs.jmedchem.0c00197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
267 Young LK, Gandy SJ, Priba L, Matthew SZ, Graeme Houston J. The Impact of Different Magnetic Resonance Imaging Equipment and Scanning Parameters on Signal Intensity Ratio Measurements in Phantoms and Healthy Volunteers: Implications for Interpreting Gadolinium Signal Changes Within the Brain. Investigative Radiology 2019;54:169-76. [DOI: 10.1097/rli.0000000000000526] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
268 Partovi S, Rasmus M, Schulte A, Rengier F, Jacob AL, Aschwanden M, Karmonik C, Bongartz G, Bilecen D. ECG-triggered non-enhanced MR angiography of peripheral arteries in comparison to DSA in patients with peripheral artery occlusive disease. Magn Reson Mater Phy 2013;26:271-80. [DOI: 10.1007/s10334-012-0352-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
269 Mathur M, Jones JR, Weinreb JC. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist’s Primer. RadioGraphics 2020;40:153-62. [DOI: 10.1148/rg.2020190110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 28.0] [Reference Citation Analysis]
270 Nörenberg D, Schmidt F, Schinke K, Frenzel T, Pietsch H, Giese A, Ertl-Wagner B, Levin J. Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS One 2020;15:e0231495. [PMID: 32324769 DOI: 10.1371/journal.pone.0231495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
271 Leach BC, Kulbersh JS, Day TA, Cook J. Cranial Neuropathy as a Presenting Sign of Recurrent Aggressive Skin Cancer. Dermatol Surg 2008;34:483-97. [DOI: 10.1111/j.1524-4725.2007.34094.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
272 Kinner S, Kuehle CA, Langhorst J, Ladd SC, Nuefer M, Barkhausen J, Lauenstein TC. MR colonography with fecal tagging: do individual patient characteristics influence image quality? J Magn Reson Imaging 2007;25:1007-12. [PMID: 17457810 DOI: 10.1002/jmri.20907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
273 Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? MAGMA 2007;20:57-62. [PMID: 17436028 DOI: 10.1007/s10334-007-0071-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
274 Zhou IY, Ramsay IA, Ay I, Pantazopoulos P, Rotile NJ, Wong A, Caravan P, Gale EM. Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A. Invest Radiol 2021;56:261-70. [PMID: 33136686 DOI: 10.1097/RLI.0000000000000736] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Semelka RC, Hernandes Mde A, Stallings CG, Castillo M. Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study. Magn Reson Imaging 2013;31:96-101. [PMID: 22898688 DOI: 10.1016/j.mri.2012.06.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
276 Zhang JL, Rusinek H, Chandarana H, Lee VS. Functional MRI of the kidneys. J Magn Reson Imaging 2013;37:282-93. [PMID: 23355431 DOI: 10.1002/jmri.23717] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
277 Amemiya S, Akahane M, Aoki S, Abe O, Kamada K, Saito N, Ohtomo K. Dynamic Contrast-Enhanced Perfusion MR Imaging With SPIO: A Pilot Study. Investigative Radiology 2009;44:503-8. [DOI: 10.1097/rli.0b013e3181b4c08f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
278 Bendszus M, Roberts D, Kolumban B, Meza JA, Bereczki D, San-juan D, Liu BP, Anzalone N, Maravilla K. Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System: . Investigative Radiology 2020;55:129-37. [DOI: 10.1097/rli.0000000000000624] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
279 Wan C, Zhan Y, Xue R, Wu Y, Li X, Pei F. Gd-DTPA-induced dynamic metabonomic changes in rat biofluids. Magn Reson Imaging 2017;44:15-25. [PMID: 28095303 DOI: 10.1016/j.mri.2017.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
280 Hanna RF, Finkelstone LA, Chow DS, Miloushev VZ, Escudero MR, Lagana SM, Prince MR. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014;2014:679605. [PMID: 24778878 DOI: 10.1155/2014/679605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
281 Liu X, Chen B, Zhang L, Song S, Cai Y, He M, Hu B. TiO₂ nanoparticles functionalized monolithic capillary microextraction online coupled with inductively coupled plasma mass spectrometry for the analysis of Gd ion and Gd-based contrast agents in human urine. Anal Chem 2015;87:8949-56. [PMID: 26239367 DOI: 10.1021/acs.analchem.5b02111] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
282 Cheong BY, Duran C, Preventza OA, Muthupillai R. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study. AJR Am J Roentgenol 2015;205:533-9. [PMID: 26295638 DOI: 10.2214/AJR.14.13749] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
283 Burrows NP, Lovell CR. Disorders of Connective Tissue. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-70. [DOI: 10.1002/9781444317633.ch45] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
284 Chen B, Zhang Y, Song X, Wang X, Zhang J, Fang J. Quantitative estimation of renal function with dynamic contrast-enhanced MRI using a modified two-compartment model. PLoS One 2014;9:e105087. [PMID: 25141138 DOI: 10.1371/journal.pone.0105087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
285 Rajendran R, Lew SK, Yong CX, Tan J, Wang DJ, Chuang KH. Quantitative mouse renal perfusion using arterial spin labeling. NMR Biomed 2013;26:1225-32. [PMID: 23592238 DOI: 10.1002/nbm.2939] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
286 Saab G, Cheng S. Nephrogenic systemic fibrosis: a nephrologist's perspective. Hemodial Int 2007;11 Suppl 3:S2-6. [PMID: 17897106 DOI: 10.1111/j.1542-4758.2007.00222.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
287 Azria D, Blanquer S, Verdier JM, Belamie E. Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis. J Mater Chem B 2017;5:7216-37. [PMID: 32264173 DOI: 10.1039/c7tb01599b] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 4.3] [Reference Citation Analysis]
288 Kendrick-jones JC, Voss DM, De Zoysa JR. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006: NSF in the Auckland region. Nephrology 2011;16:243-8. [DOI: 10.1111/j.1440-1797.2010.01397.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
289 Leyendecker JR, Gianini JW. Magnetic resonance urography. Abdom Imaging 2009;34:527-40. [PMID: 18463916 DOI: 10.1007/s00261-008-9403-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
290 Yang C, Padmanabhan P, Gulyás BZ. Gadolinium( iii ) based nanoparticles for T 1 -weighted magnetic resonance imaging probes. RSC Adv 2016;6:60945-66. [DOI: 10.1039/c6ra07782j] [Cited by in Crossref: 27] [Article Influence: 5.4] [Reference Citation Analysis]
291 Edelman RR, Koktzoglou I. Noncontrast MR angiography: An update. J Magn Reson Imaging 2019;49:355-73. [PMID: 30566270 DOI: 10.1002/jmri.26288] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
292 Chaudhary R, Roy K, Kanwar RK, Walder K, Kanwar JR. Engineered atherosclerosis-specific zinc ferrite nanocomplex-based MRI contrast agents. J Nanobiotechnology 2016;14:6. [PMID: 26775253 DOI: 10.1186/s12951-016-0157-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
293 Grebe SO, Borrmann M, Altenburg A, Wesselman U, Hein D, Haage P. Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. Clin Exp Nephrol 2008;12:403-6. [DOI: 10.1007/s10157-008-0063-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
294 Radbruch A, Richter H, Bücker P, Berlandi J, Schänzer A, Deike-Hofmann K, Kleinschnitz C, Schlemmer HP, Forsting M, Paulus W, Martin LF, van Thriel C, Karst U, Jeibmann A. Is Small Fiber Neuropathy Induced by Gadolinium-Based Contrast Agents? Invest Radiol 2020;55:473-80. [PMID: 32604384 DOI: 10.1097/RLI.0000000000000677] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
295 Ding B, Liu K, Zhang F, Wang Y, Cheng S, Lu Y, Qian H. Facile synthesis of β-NaGdF 4 :Yb/Er@CaF 2 nanoparticles with enhanced upconversion fluorescence and stability via a sequential growth process. CrystEngComm 2015;17:5900-5. [DOI: 10.1039/c5ce01061f] [Cited by in Crossref: 10] [Article Influence: 1.7] [Reference Citation Analysis]
296 Thomsen HS, Morcos SK. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT – A pooled analysis of two randomized trials. Eur Radiol 2009;19:891-7. [DOI: 10.1007/s00330-008-1206-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
297 Reeves C, Galang E, Padalia R, Tran N, Padalia D. Intrathecal Injection of Gadobutrol: A Tale of Caution. Journal of Pain & Palliative Care Pharmacotherapy 2017;31:139-43. [DOI: 10.1080/15360288.2017.1313353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
298 Bae S, Lee H, Han K, Park Y, Choi YS, Ahn SS, Kim J, Lee S. Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. Eur Radiol 2017;27:3353-61. [DOI: 10.1007/s00330-016-4724-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
299 Malikova H, Holesta M. Gadolinium Contrast Agents - Are they Really Safe? J Vasc Access 2017;18:S1-7. [DOI: 10.5301/jva.5000713] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
300 Ziylan F, Smeeing DPJ, Stegeman I, Thomeer HGXM. Click Stimulus Electrocochleography Versus MRI With Intratympanic Contrast in Ménière's Disease: A Systematic Review. Otology & Neurotology 2016;37:421-7. [DOI: 10.1097/mao.0000000000001021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
301 Schmidt MH, Downie J. Safety first: Recognizing and managing the risks to child participants in magnetic resonance imaging research. Account Res 2009;16:153-73. [PMID: 20183159 DOI: 10.1080/08989620902984106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
302 Stanescu AL, Shaw DW, Murata N, Murata K, Rutledge JC, Maloney E, Maravilla KR. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol 2020;50:388-96. [DOI: 10.1007/s00247-019-04535-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
303 Perazella MA, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Recommendations for Gadolinium-Based Contrast Use in Patients with Kidney Disease: GUIDELINES OF GBC USE IN KIDNEY DISEASE. Seminars in Dialysis 2008;21:171-3. [DOI: 10.1111/j.1525-139x.2007.00402.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
304 Agid R, Willinsky RA, Lee SK, Terbrugge KG, Farb RI. Characterization of aneurysm remnants after endovascular treatment: contrast-enhanced MR angiography versus catheter digital subtraction angiography. AJNR Am J Neuroradiol 2008;29:1570-4. [PMID: 18499789 DOI: 10.3174/ajnr.A1124] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
305 Motegi S, Okada E, Uchiyama A, Yamada K, Ogino S, Yokoyama Y, Takeuchi Y, Monma F, Suzuki T, Ishikawa O. Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. Exp Dermatol 2014;23:664-9. [DOI: 10.1111/exd.12500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
306 Steen H, Giannitsis E, Sommerer C, Bahner U, Brandl M, Merbach C, Merten C, Ritz E, Katus HA, Zeier M, Schwenger V. Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant 2009;24:1274-7. [PMID: 19042926 DOI: 10.1093/ndt/gfn655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
307 Brücher E, Tircsó G, Baranyai Z, Kovács Z, Sherry AD. Stability and Toxicity of Contrast Agents. In: Merbach A, Helm L, Tóth É, editors. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chichester: John Wiley & Sons, Ltd; 2013. pp. 157-208. [DOI: 10.1002/9781118503652.ch4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
308 Su HS, Nazarian RM, Scott JA. Appearance of nephrogenic fibrosing dermopathy on a bone scan. BJR 2009;82:e35-6. [DOI: 10.1259/bjr/20570152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
309 Di Gregorio E, Iani R, Ferrauto G, Nuzzi R, Aime S, Gianolio E. Gd accumulation in tissues of healthy mice upon repeated administrations of Gadodiamide and Gadoteridol. Journal of Trace Elements in Medicine and Biology 2018;48:239-45. [DOI: 10.1016/j.jtemb.2018.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
310 Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82-8. [PMID: 22833806 DOI: 10.1093/ckj/sfr172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
311 Nelson BB, Goodrich LR, Barrett MF, Grinstaff MW, Kawcak CE. Use of contrast media in computed tomography and magnetic resonance imaging in horses: Techniques, adverse events and opportunities. Equine Vet J 2017;49:410-24. [DOI: 10.1111/evj.12689] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
312 Morita S, Suzuki K, Masukawa A, Ueno E. Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. Jpn J Radiol 2011;29:187-93. [DOI: 10.1007/s11604-010-0536-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
313 Künnemeyer J, Terborg L, Nowak S, Brauckmann C, Telgmann L, Albert A, Tokmak F, Krämer BK, Günsel A, Wiesmüller GA, Karst U. Quantification and excretion kinetics of a magnetic resonance imaging contrast agent by capillary electrophoresis-mass spectrometry. Electrophoresis 2009;30:1766-73. [DOI: 10.1002/elps.200800831] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
314 Cameli M, Mandoli GE, Loiacono F, Sparla S, Iardino E, Mondillo S. Left atrial strain: A useful index in atrial fibrillation. International Journal of Cardiology 2016;220:208-13. [DOI: 10.1016/j.ijcard.2016.06.197] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
315 Kanda T, Oba H, Toyoda K, Kitajima K, Furui S. Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016;34:3-9. [DOI: 10.1007/s11604-015-0503-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 85] [Article Influence: 17.3] [Reference Citation Analysis]
316 Gupta A, Caravan P, Price WS, Platas-Iglesias C, Gale EM. Applications for Transition-Metal Chemistry in Contrast-Enhanced Magnetic Resonance Imaging. Inorg Chem 2020;59:6648-78. [PMID: 32367714 DOI: 10.1021/acs.inorgchem.0c00510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 19.0] [Reference Citation Analysis]
317 Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned. American Journal of Roentgenology 2007;188:586-92. [DOI: 10.2214/ajr.06.1094] [Cited by in Crossref: 463] [Cited by in F6Publishing: 73] [Article Influence: 33.1] [Reference Citation Analysis]
318 Hyland K, Cohen RM, Kwak A, Shlansky-goldberg RD, Soulen MC, Patel AA, Mondschein JI, Solomon JA, Stavropoulos SW, Itkin M, Yeh H, Markmann J, Trerotola SO. Preoperative Mapping Venography in Patients Who Require Hemodialysis Access: Imaging Findings and Contribution to Management. Journal of Vascular and Interventional Radiology 2008;19:1027-33. [DOI: 10.1016/j.jvir.2008.03.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
319 Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data. World J Radiol. 2010;2:427-433. [PMID: 21179310 DOI: 10.4329/wjr.v2.i11.427] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
320 Kee PH, Danila D. CT imaging of myocardial scar burden with CNA35-conjugated gold nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine 2018;14:1941-7. [DOI: 10.1016/j.nano.2018.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
321 Swaminathan S. Gadolinium toxicity: Iron and ferroportin as central targets. Magn Reson Imaging 2016;34:1373-6. [PMID: 27580520 DOI: 10.1016/j.mri.2016.08.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
322 Kalb B, Votaw JR, Salman K, Sharma P, Martin DR. Magnetic resonance nephrourography: current and developing techniques. Radiol Clin North Am. 2008;46:11-24, v. [PMID: 18328877 DOI: 10.1016/j.rcl.2008.01.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
323 Jhooti P, Haas T, Kawel N, Bremerich J, Keegan J, Scheffler K. Use of respiratory biofeedback and CLAWS for increased navigator efficiency for imaging the thoracic aorta. Magn Reson Med 2011;66:1666-73. [PMID: 21523822 DOI: 10.1002/mrm.22945] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
324 Fischer A, Kraff O, Maderwald S, Beiderwellen K, Ladd ME, Forsting M, Lauenstein TC, Umutlu L. Non-enhanced T1-weighted liver vessel imaging at 7 Tesla. PLoS One 2014;9:e97465. [PMID: 24887206 DOI: 10.1371/journal.pone.0097465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
325 Waugh SA, Ramkumar PG, Gandy SJ, Nicholas RS, Martin P, Belch JJ, Struthers AD, Houston JG. Optimization of the contrast dose and injection rates in whole-body MR angiography at 3.0T. J Magn Reson Imaging 2009;30:1059-67. [PMID: 19856438 DOI: 10.1002/jmri.21930] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
326 Kirchin MA, Lorusso V, Pirovano G. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 2015;88:20140526. [PMID: 25651409 DOI: 10.1259/bjr.20140526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
327 Li B, Li Q, Chen C, Guan Y, Liu S. Diagnostic accuracy of computer tomography angiography and magnetic resonance angiography in the stenosis detection of autologuous hemodialysis access: a meta-analysis. PLoS One 2013;8:e78409. [PMID: 24194928 DOI: 10.1371/journal.pone.0078409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
328 Tear LR, Maguire ML, Tropiano M, Yao K, Farrer NJ, Faulkner S, Schneider JE. Enhancing 31P NMR relaxation rates with a kinetically inert gadolinium complex. Dalton Trans 2020;49:2989-93. [PMID: 32080690 DOI: 10.1039/c9dt03761f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
329 Zhang JL. Functional Magnetic Resonance Imaging of the Kidneys-With and Without Gadolinium-Based Contrast. Adv Chronic Kidney Dis 2017;24:162-8. [PMID: 28501079 DOI: 10.1053/j.ackd.2017.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
330 Dawson P. Nephrogenic systemic fibrosis: Possible mechanisms and imaging management strategies. J Magn Reson Imaging 2008;28:797-804. [DOI: 10.1002/jmri.21521] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
331 Jao SY, Yang BY, Weng HH, Yeh CH, Lee LW. Evaluation of gadolinium-enhanced T1-weighted magnetic resonance imaging in the preoperative assessment of local staging in rectal cancer. Colorectal Dis. 2010;12:1139-1148. [PMID: 19548900 DOI: 10.1111/j.1463-1318.2009.01959.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
332 Tombach B, Bohndorf K, Brodtrager W, Claussen CD, Düber C, Galanski M, Grabbe E, Gortenuti G, Kuhn M, Gross-fengels W, Hammerstingl R, Happel B, Heinz-peer G, Jung G, Kittner T, Lagalla R, Lengsfeld P, Loose R, Oyen RHG, Pavlica P, Pering C, Pozzi-mucelli R, Persigehl T, Reimer P, Renken NS, Richter GM, Rummeny EJ, Schäfer F, Szczerbo-trojanowska M, Urbanik A, Vogl TJ, Hajek P. Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial. Eur Radiol 2008;18:2610-9. [DOI: 10.1007/s00330-008-1054-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
333 Panesar M, Boateng F, Patel SS, Masood SF, Mahajan P, Patel N, Murray B. Transmetallation and gadolinium: Do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?: Gadopentetate and transmetallation. Hemodialysis International 2010;14:289-94. [DOI: 10.1111/j.1542-4758.2010.00456.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
334 High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. Gadolinium deposition in nephrogenic systemic fibrosis: An examination of tissue using synchrotron x-ray fluorescence spectroscopy. Journal of the American Academy of Dermatology 2010;62:38-44. [DOI: 10.1016/j.jaad.2009.07.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
335 Garda Z, Nagy V, Rodríguez-rodríguez A, Pujales-paradela R, Patinec V, Angelovski G, Tóth É, Kálmán FK, Esteban-gómez D, Tripier R, Platas-iglesias C, Tircsó G. Unexpected Trends in the Stability and Dissociation Kinetics of Lanthanide(III) Complexes with Cyclen-Based Ligands across the Lanthanide Series. Inorg Chem 2020;59:8184-95. [DOI: 10.1021/acs.inorgchem.0c00520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
336 Kraff O, Ladd ME. MR Safety Update 2015: Where Do the Risks Come From? Curr Radiol Rep 2016;4. [DOI: 10.1007/s40134-016-0163-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
337 Wang T, Hossann M, Reinl HM, Peller M, Eibl H, Reiser M, Issels RD, Lindner LH. In vitro characterization of phosphatidylglyceroglycerol-based thermosensitive liposomes with encapsulated1H MRT1-shortening gadodiamide. Contrast Media Mol Imaging 2008;3:19-26. [DOI: 10.1002/cmmi.226] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
338 Gongalsky MB, Kargina YV, Osminkina LA, Perepukhov AM, Gulyaev MV, Vasiliev AN, Pirogov YA, Maximychev AV, Timoshenko VY. Porous silicon nanoparticles as biocompatible contrast agents for magnetic resonance imaging. Appl Phys Lett 2015;107:233702. [DOI: 10.1063/1.4937731] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 5.2] [Reference Citation Analysis]
339 Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol. 2008;158:607-610. [PMID: 18076707 DOI: 10.1111/j.1365-2133.2007.08369.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
340 Brünjes R, Hofmann T. Anthropogenic gadolinium in freshwater and drinking water systems. Water Res 2020;182:115966. [PMID: 32599421 DOI: 10.1016/j.watres.2020.115966] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
341 Pei Y, Shen H, Li J, Zhang H, Xia L, Wang L, Hu D. Evaluation of Renal Artery in Hypertensive Patients by Unenhanced MR Angiography Using Spatial Labeling With Multiple Inversion Pulses Sequence and by CT Angiography. American Journal of Roentgenology 2012;199:1142-8. [DOI: 10.2214/ajr.11.7263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
342 Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008;21:469-90. [PMID: 18344005 DOI: 10.1007/s10534-008-9135-x] [Cited by in Crossref: 254] [Cited by in F6Publishing: 205] [Article Influence: 19.5] [Reference Citation Analysis]
343 Braidy C, Daou I, Diop AD, Helweh O, Gageanu C, Boyer L, Chabrot P. Unenhanced MR Angiography of Renal Arteries: 51 Patients. American Journal of Roentgenology 2012;199:W629-37. [DOI: 10.2214/ajr.12.8513] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
344 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
345 Kim S, Jain M, Harris AB, Lee VS, Babb JS, Sigmund EE, Rueff LE, Taouli B. T1 Hyperintense Renal Lesions: Characterization with Diffusion-weighted MR Imaging versus Contrast-enhanced MR Imaging. Radiology 2009;251:796-807. [DOI: 10.1148/radiol.2513080724] [Cited by in Crossref: 89] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
346 Hillengass J, Stoll J, Zechmann CM, Kunz C, Wagner B, Heiss C, Sumkauskaite M, Moehler TM, Schlemmer HP, Goldschmidt H, Delorme S. The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. Eur Radiol 2015;25:745-50. [PMID: 25358594 DOI: 10.1007/s00330-014-3458-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
347 McHugh CT, Durham PG, Kelley M, Dayton PA, Branca RT. Magnetic Resonance Detection of Gas Microbubbles via HyperCEST: A Path Toward Dual Modality Contrast Agent. Chemphyschem 2021;22:1219-28. [PMID: 33852753 DOI: 10.1002/cphc.202100183] [Reference Citation Analysis]
348 Elbeshlawi I, Abdelbaki MS. Safety of Gadolinium Administration in Children. Pediatric Neurology 2018;86:27-32. [DOI: 10.1016/j.pediatrneurol.2018.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
349 Walker JP, Nosova E, Sigovan M, Rapp J, Grenon MS, Owens CD, Gasper WJ, Saloner DA. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. Ann Vasc Surg 2015;29:63-8. [PMID: 25269682 DOI: 10.1016/j.avsg.2014.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
350 Liszewski MC, Görkem S, Sodhi KS, Lee EY. Lung magnetic resonance imaging for pneumonia in children. Pediatr Radiol 2017;47:1420-30. [PMID: 29043418 DOI: 10.1007/s00247-017-3865-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
351 Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
352 Zaharchuk G, Martin AJ, Dillon WP. Noninvasive imaging of quantitative cerebral blood flow changes during 100% oxygen inhalation using arterial spin-labeling MR imaging. AJNR Am J Neuroradiol 2008;29:663-7. [PMID: 18397966 DOI: 10.3174/ajnr.A0896] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
353 Cline B, Hurwitz LM, Kim CY. MR Venography of the Central Veins of the Thorax. Top Magn Reson Imaging 2017;26:167-74. [PMID: 28777165 DOI: 10.1097/RMR.0000000000000139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
354 Vivier PH, Dolores M, Taylor M, Elbaz F, Liard A, Dacher JN. MR urography in children. Part 1: how we do the F0 technique. Pediatr Radiol 2010;40:732-8. [PMID: 20182706 DOI: 10.1007/s00247-009-1538-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
355 Dworkin LD, Cooper CJ. Clinical practice. Renal-artery stenosis. N Engl J Med 2009;361:1972-8. [PMID: 19907044 DOI: 10.1056/NEJMcp0809200] [Cited by in Crossref: 109] [Cited by in F6Publishing: 6] [Article Influence: 9.1] [Reference Citation Analysis]
356 Nadolski GJ, Stavropoulos SW. Contrast alternatives for iodinated contrast allergy and renal dysfunction: options and limitations. J Vasc Surg. 2013;57:593-598. [PMID: 23246079 DOI: 10.1016/j.jvs.2012.10.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
357 Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances in Dermatology 2007;23:131-54. [DOI: 10.1016/j.yadr.2007.07.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
358 Hou X, Zhou H, Wang L, Tang J, Chen C, Jiang G, Liu Y. Multifunctional near-infrared dye-magnetic nanoparticles for bioimaging and cancer therapy. Cancer Letters 2017;390:168-75. [DOI: 10.1016/j.canlet.2016.12.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
359 Grand DJ, Harris A, Loftus EV. Imaging for Luminal Disease and Complications: CT Enterography, MR Enterography, Small-Bowel Follow-Through, and Ultrasound. Gastroenterology Clinics of North America 2012;41:497-512. [DOI: 10.1016/j.gtc.2012.01.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
360 Piersson A, Gorleku P. The use of gadolinium-based contrast agents in Ghana with a focus on residual intracranial gadolinium deposition. Radiography 2018;24:e51-5. [DOI: 10.1016/j.radi.2017.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, Lee VS, Israel GM. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251:398-407. [PMID: 19276322 DOI: 10.1148/radiol.2512080880] [Cited by in Crossref: 240] [Cited by in F6Publishing: 184] [Article Influence: 20.0] [Reference Citation Analysis]
362 Hammerstingl R, Adam G, Ayuso J, Van Beers B, Belfiore G, Bellin M, Bongartz G, Ernst O, Frericks B, Giuseppetti G, Heinz-peer G, Laghi A, Martin J, Pering C, Reimer P, Richter G, Roemer FW, Schäfer FKW, Vilgrain V, Vogl TJ, Weishaupt D, Wall A, Zech CJ, Tombach B. Comparison of 1.0 M Gadobutrol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions: Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial. Investigative Radiology 2009;44:168-76. [DOI: 10.1097/rli.0b013e318198a0ae] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
363 Liszewski MC, Ciet P, Sodhi KS, Lee EY. Updates on MRI Evaluation of Pediatric Large Airways. American Journal of Roentgenology 2017;208:971-81. [DOI: 10.2214/ajr.16.17132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
364 Mori K, Saida T, Sato F, Uchikawa Y, Konishi T, Ishiguro T, Hiyama T, Hoshiai S, Okamoto Y, Nasu K, Minami M. Endoleak detection after endovascular aneurysm repair using unenhanced MRI with flow suppression technique: Feasibility study in comparison with contrast-enhanced CT. Eur Radiol 2017;27:336-44. [PMID: 27011375 DOI: 10.1007/s00330-016-4315-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
365 Buckley O, Rybicki FJ, Gerson DS, Huether C, Prior RF, Powers SL, Ersoy H. Imaging features of intramural hematoma of the aorta. Int J Cardiovasc Imaging 2010;26:65-76. [PMID: 19777368 DOI: 10.1007/s10554-009-9504-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
366 Kim SY, Maurer MH, Richter JK, Heverhagen JT, Boehm IB. Gadolinium depositions after the application of the hepatospecific gadolinium-based contrast agent gadoxetate disodium. European Journal of Internal Medicine 2018;47:e9-e11. [DOI: 10.1016/j.ejim.2017.09.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
367 Riccabona M, Dacher J, Olsen ØE, Claudon M, Fotter R. Gadolinium and Nephrogenic Systemic Fibrosis. In: Fotter R, editor. Pediatric Uroradiology. Berlin: Springer Berlin Heidelberg; 2008. pp. 515-7. [DOI: 10.1007/978-3-540-33005-9_29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
368 Lord ML, Chettle DR, Gräfe JL, Noseworthy MD, Mcneill FE. Observed Deposition of Gadolinium in Bone Using a New Noninvasive in Vivo Biomedical Device: Results of a Small Pilot Feasibility Study. Radiology 2018;287:96-103. [DOI: 10.1148/radiol.2017171161] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
369 Lim SP, Mc Ardle BA, Beanlands RS, Hessian RC. Myocardial Viability: It is Still Alive. Seminars in Nuclear Medicine 2014;44:358-74. [DOI: 10.1053/j.semnuclmed.2014.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
370 Ramaizel L, Sliwa JA. Rehabilitation in Nephrogenic Systemic Fibrosis. PM&R 2009;1:684-6. [DOI: 10.1016/j.pmrj.2009.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
371 Bridges MD, St. Amant BS, Mcneil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM. High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function. American Journal of Roentgenology 2009;192:1538-43. [DOI: 10.2214/ajr.07.3895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
372 Penfield JG, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium-Based Contrast Agents?: GADOLINIUM CHELATE DIFFERENCES AND NSF RISK. Seminars in Dialysis 2008;21:129-34. [DOI: 10.1111/j.1525-139x.2007.00408.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
373 Chan JMW, Wojtecki RJ, Sardon H, Lee ALZ, Smith CE, Shkumatov A, Gao S, Kong H, Yang YY, Hedrick JL. Self-Assembled, Biodegradable Magnetic Resonance Imaging Agents: Organic Radical-Functionalized Diblock Copolymers. ACS Macro Lett 2017;6:176-80. [DOI: 10.1021/acsmacrolett.6b00924] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
374 Pushie MJ, Pickering IJ, Korbas M, Hackett MJ, George GN. Elemental and chemically specific X-ray fluorescence imaging of biological systems. Chem Rev 2014;114:8499-541. [PMID: 25102317 DOI: 10.1021/cr4007297] [Cited by in Crossref: 158] [Cited by in F6Publishing: 112] [Article Influence: 22.6] [Reference Citation Analysis]
375 Scott LJ. Gadobutrol: A Review in Contrast-Enhanced MRI and MRA. Clin Drug Investig 2018;38:773-84. [PMID: 30006819 DOI: 10.1007/s40261-018-0674-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
376 Schietinger BJ, Brammer GM, Wang H, Christopher JM, Kwon KW, Mangrum AJ, Mangrum JM, Kramer CM. Patterns of late gadolinium enhancement in chronic hemodialysis patients. JACC Cardiovasc Imaging 2008;1:450-6. [PMID: 19356466 DOI: 10.1016/j.jcmg.2008.03.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
377 Hoggard N, Roditi GH. T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition? Br J Radiol 2017;90:20160590. [PMID: 27653560 DOI: 10.1259/bjr.20160590] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
378 Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2017-23. [PMID: 20570839 DOI: 10.1136/ard.2009.127761] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
379 Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647-649. [PMID: 17213364 DOI: 10.1148/radiol.2423061640] [Cited by in Crossref: 448] [Cited by in F6Publishing: 332] [Article Influence: 32.0] [Reference Citation Analysis]
380 Liu HS, Jawad AF, Laney N, Hartung EA, Furth SL, Detre JA. Effect of blood T1 estimation strategy on arterial spin labeled cerebral blood flow quantification in children and young adults with kidney disease. J Neuroradiol 2019;46:29-35. [PMID: 29604324 DOI: 10.1016/j.neurad.2018.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
381 Idée J, Fretellier N, Thurnher M, Bonnemain B, Corot C. Physico-chimie et profil toxicologique d’agents de contraste pour l’imagerie par résonance magnétique, les chélates de gadolinium. Annales Pharmaceutiques Françaises 2015;73:266-76. [DOI: 10.1016/j.pharma.2015.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
382 Voth M, Michaely HJ, Schwenke C, Vos B, Pietsch H. Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla. Eur Radiol 2011;21:337-44. [DOI: 10.1007/s00330-010-1940-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
383 Maloo M, Abt P, Kashyap R, Younan D, Zand M, Orloff M, Jain A, Pentland A, Scott G, Bozorgzadeh A. Nephrogenic Systemic Fibrosis Among Liver Transplant Recipients: A Single Institution Experience and Topic Update. Am J Transplant 2006;6:2212-7. [DOI: 10.1111/j.1600-6143.2006.01420.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
384 Chandrasekharan P, Yong C, Poh Z, He T, He Z, Liu S, Robins EG, Chuang K, Yang C. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent. Biomaterials 2012;33:9225-31. [DOI: 10.1016/j.biomaterials.2012.08.071] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
385 Little JT, Bookwalter CA. Magnetic Resonance Safety: Pregnancy and Lactation. Magn Reson Imaging Clin N Am 2020;28:509-16. [PMID: 33040992 DOI: 10.1016/j.mric.2020.06.002] [Reference Citation Analysis]
386 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
387 Caneda-Martínez L, Valencia L, Fernández-Pérez I, Regueiro-Figueroa M, Angelovski G, Brandariz I, Esteban-Gómez D, Platas-Iglesias C. Toward inert paramagnetic Ni(ii)-based chemical exchange saturation transfer MRI agents. Dalton Trans 2017;46:15095-106. [PMID: 29067395 DOI: 10.1039/c7dt02758c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
388 Li Q, Chen K, Huang W, Ma H, Zhao X, Zhang J, Zhang Y, Fang C, Nie L. Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma. Cancer Lett 2021;496:169-78. [PMID: 32987139 DOI: 10.1016/j.canlet.2020.09.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
389 Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, Meshinchi S, Bhagavathula N, Varani J. Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 2012;145:257-67. [PMID: 21882070 DOI: 10.1007/s12011-011-9176-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
390 Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-263. [PMID: 17699422 DOI: 10.2215/cjn.03250906] [Cited by in Crossref: 108] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
391 Wolf ME, Layer V, Gregori J, Griebe M, Szabo K, Gass A, Hennerici MG, Günther M, Kern R. Assessment of Perfusion Deficits in Ischemic Stroke Using 3D-GRASE Arterial Spin Labeling Magnetic Resonance Imaging with Multiple Inflow Times: Multi-TI-3D-GRASE ASL Imaging in Ischemic Stroke. J Neuroimaging 2014;24:453-9. [DOI: 10.1111/jon.12064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
392 Martí-bonmatí L, Martí-bonmatí E. Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias. Radiología 2017;59:469-77. [DOI: 10.1016/j.rx.2017.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
393 Schueller-weidekamm C, Lodemann K, Grisar J, Schueller G, Weber M, Kainberger F, Platzgummer H. Contrast-enhanced MR Imaging of Hand and Finger Joints in Patients with Early Rheumatoid Arthritis: Do We Really Need a Full Dose of Gadobenate Dimeglumine for Assessing Synovial Enhancement at 3 T? Radiology 2013;268:161-9. [DOI: 10.1148/radiol.13121733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
394 Elmholdt T, Pedersen M, Jørgensen B, Søndergaard K, Jensen J, Ramsing M, Olesen A. Nephrogenic systemic fibrosis is found only among gadolinium‐exposed patients with renal insufficiency: a case–control study from Denmark. British Journal of Dermatology 2011;165:828-36. [DOI: 10.1111/j.1365-2133.2011.10465.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
395 Zhou X, Sun Y, Mazzanti M, Henninger N, Mansour J, Fisher M, Albert M. MRI of stroke using hyperpolarized 129Xe. NMR Biomed 2011;24:170-5. [PMID: 20821723 DOI: 10.1002/nbm.1568] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
396 Prola-Netto J, Woods M, Roberts VHJ, Sullivan EL, Miller CA, Frias AE, Oh KY. Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure. Radiology 2018;286:122-8. [PMID: 28873045 DOI: 10.1148/radiol.2017162534] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
397 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
398 De Vis JB, Petersen ET, Hendrikse J. Arterial Spin Labeling Magnetic Resonance Imaging. PET Clinics 2013;8:295-309. [DOI: 10.1016/j.cpet.2013.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
399 Vivier PH, Storey P, Rusinek H, Zhang JL, Yamamoto A, Tantillo K, Khan U, Lim RP, Babb JS, John D, Teperman LW, Chandarana H, Friedman K, Benstein JA, Skolnik EY, Lee VS. Kidney function: glomerular filtration rate measurement with MR renography in patients with cirrhosis. Radiology 2011;259:462-70. [PMID: 21386050 DOI: 10.1148/radiol.11101338] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
400 Vaeggemose M, F Schulte R, Laustsen C. Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application. Metabolites 2021;11:219. [PMID: 33916803 DOI: 10.3390/metabo11040219] [Reference Citation Analysis]
401 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
402 Lange S, Mędrzycka-Dąbrowska W, Zorena K, Dąbrowski S, Ślęzak D, Malecka-Dubiela A, Rutkowski P. Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review. Int J Environ Res Public Health 2021;18:3000. [PMID: 33804005 DOI: 10.3390/ijerph18063000] [Reference Citation Analysis]
403 Sambol EB, Van der Meer JG, Graham A, Goldstein LJ, Karwowski JK, Dayal R, Derubertis B, Kent KC. The use of gadolinium for arterial interventions. Ann Vasc Surg 2011;25:366-76. [PMID: 21288688 DOI: 10.1016/j.avsg.2010.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
404 Bahrainwala JZ, Leonberg-yoo AK, Rudnick MR. Use of Radiocontrast Agents in CKD and ESRD. Semin Dial 2017;30:290-304. [DOI: 10.1111/sdi.12593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
405 Thakral C, Abraham JL. Nephrogenic Systemic Fibrosis: Histology and Gadolinium Detection. Radiologic Clinics of North America 2009;47:841-53. [DOI: 10.1016/j.rcl.2009.06.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
406 Singh M, Davenport A, Clatworthy I, Lewin J, Deroide F, Hubbard V, Rustin MH. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 2008;158:1358-62. [PMID: 18363754 DOI: 10.1111/j.1365-2133.2008.08506.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
407 Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;25:881-3. [DOI: 10.1002/jmri.20983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
408 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
409 Tumkosit M, Puntawangkoon C, Morgan TM, Clark HP, Hamilton CA, Ntim WO, Clark PB, Hundley WG. Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine. J Comput Assist Tomogr 2009;33:328-33. [PMID: 19478622 DOI: 10.1097/RCT.0b013e318187fed0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
410 Giersig C. Nephrogene systemische Fibrose als unerwünschte Arzneimittelwirkung gadoliniumhaltiger Kontrastmittel für die Magnetresonanztomographie. Radiologe 2007;47:794-9. [DOI: 10.1007/s00117-007-1543-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
411 Ishisaki JY, Kato H, Zhang X, Kuwatsuru Y, Miyazaki H, Sato S, Kuwatsuru R. Comparison of 1.5 T and 3 T non-contrast-enhanced MR angiography for visualization of uterine and ovarian arteries before uterine artery embolization. Eur Radiol 2021. [PMID: 34195889 DOI: 10.1007/s00330-021-08141-z] [Reference Citation Analysis]
412 Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175. [PMID: 17704357 DOI: 10.1148/radiol.2451070353] [Cited by in Crossref: 247] [Cited by in F6Publishing: 188] [Article Influence: 17.6] [Reference Citation Analysis]
413 Wu Q, Li MH. A comparison of 4D time-resolved MRA with keyhole and 3D time-of-flight MRA at 3.0 T for the evaluation of cerebral aneurysms. BMC Neurol 2012;12:50. [PMID: 22784396 DOI: 10.1186/1471-2377-12-50] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
414 Lim RP, Trajcevska E, Al Rawi F, Gooneratne D, Ang W, Perchyonok Y, Fitt G, Kemp A, Giri S, Piccini D, Brodtmann A, Dewey H, Koktzoglou I. Noncontrast Hybrid Arterial Spin-Labeled Imaging of the Intracranial Arteries: . Journal of Computer Assisted Tomography 2017;41:854-60. [DOI: 10.1097/rct.0000000000000633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
415 Shen ZT, Zheng S, Gounis MJ, Sigalov AB. Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles. PLoS One 2015;10:e0143453. [PMID: 26569115 DOI: 10.1371/journal.pone.0143453] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
416 Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: A single-center experience. Journal of the American Academy of Dermatology 2010;63:389-99. [DOI: 10.1016/j.jaad.2009.10.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
417 Kiss T, Enyedy ÉA, Jakusch T. Development of the application of speciation in chemistry. Coordination Chemistry Reviews 2017;352:401-23. [DOI: 10.1016/j.ccr.2016.12.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
418 Muhs BE, Verhagen HJ, Huddle MG, Pai VM, Hecht EM, Dardik A. Theory, technique, and practice of magnetic resonance angiography. Vascular 2007;15:376-83. [PMID: 18053424 DOI: 10.2310/6670.2007.00052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
419 Foss C, Smith JK, Ortiz L, Hanevold C, Davis L. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy. Pediatr Dermatol 2009;26:579-82. [PMID: 19840315 DOI: 10.1111/j.1525-1470.2008.00802.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
420 Leiner T, Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009;30:1233-5. [PMID: 19938034 DOI: 10.1002/jmri.21985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
421 Li X, Chen H, Liu F, Chen Y, Zhang H, Wang Z. Accurate Monitoring of Renal Injury State through in Vivo Magnetic Resonance Imaging with Ferric Coordination Polymer Nanodots. ACS Omega 2018;3:4918-23. [PMID: 30221228 DOI: 10.1021/acsomega.8b00514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Dai L, Jones CM, Chan WTK, Pham TA, Ling X, Gale EM, Rotile NJ, Tai WC, Anderson CJ, Caravan P, Law GL. Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications. Nat Commun 2018;9:857. [PMID: 29487362 DOI: 10.1038/s41467-018-03315-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 12.3] [Reference Citation Analysis]
423 McKoy JM, Laumann A, Samaras A, Lacouture M, West D, Raisch D, Obadina E, Fajolu O, Reilly L, Bennett CL. Gadolinium-associated nephrogenic systemic fibrosis. Community Oncol 2008;5:325-6. [PMID: 19920874 DOI: 10.1016/s1548-5315(11)70463-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
424 Rydahl C, Thomsen HS, Marckmann P. High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent: . Investigative Radiology 2008;43:141-4. [DOI: 10.1097/rli.0b013e31815a3407] [Cited by in Crossref: 199] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
425 Thomsen HS, Bennett CL. Six years after. Acta Radiol 2012;53:827-9. [PMID: 23060466 DOI: 10.1258/ar.2012.12a005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
426 Coll DM, Smith RC. Update on radiological imaging of renal cell carcinoma. BJU Int. 2007;99:1217-1222. [PMID: 17441914 DOI: 10.1111/j.1464-410x.2007.06824.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
427 Dawson P, Punwani S. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Non-Gadolinium Options for the Imaging of CKD/ESRD Patients: NSF AND IMAGING STRATEGIES. Seminars in Dialysis 2008;21:160-5. [DOI: 10.1111/j.1525-139x.2007.00401.x] [Cited by in Crossref: 17] [Article Influence: 1.3] [Reference Citation Analysis]
428 Wiginton CD. Implications of NSF-Active and NSF-Inert in Nephrogenic Systemic Fibrosis. American Journal of Roentgenology 2008;191:1864-6. [DOI: 10.2214/ajr.08.1410] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
429 Kahakachchi CL, Moore DA. Identification and characterization of gadolinium(iii) complexes in biological tissue extracts. Metallomics 2010;2:490. [DOI: 10.1039/b915806e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
430 Jenjob R, Kun N, Ghee JY, Shen Z, Wu X, Cho SK, Lee DH, Yang S. Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. Materials Science and Engineering: C 2016;61:659-64. [DOI: 10.1016/j.msec.2016.01.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
431 Semelka RC, Ramalho J, Vakharia A, Alobaidy M, Burke LM, Jay M, Ramalho M. Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magnetic Resonance Imaging 2016;34:1383-90. [DOI: 10.1016/j.mri.2016.07.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 16.4] [Reference Citation Analysis]
432 Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-53. [PMID: 28083913 DOI: 10.1002/jmri.25625] [Cited by in Crossref: 168] [Cited by in F6Publishing: 118] [Article Influence: 42.0] [Reference Citation Analysis]
433 Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 2014;87:20140307. [PMID: 25230161 DOI: 10.1259/bjr.20140307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
434 Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol. 2008;5:45-52. [PMID: 18180009 DOI: 10.1016/j.jacr.2007.08.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
435 Chandra T, Mohan S. Role of Contrast in MR Imaging. Topics in Magnetic Resonance Imaging 2016;25:151-6. [DOI: 10.1097/rmr.0000000000000094] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
436 Erstad DJ, Ramsay IA, Jordan VC, Sojoodi M, Fuchs BC, Tanabe KK, Caravan P, Gale EM. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. Invest Radiol 2019;54:697-703. [PMID: 31356382 DOI: 10.1097/RLI.0000000000000593] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 20.0] [Reference Citation Analysis]
437 Thomsen HS. T1 hyperintensity in the brain after multiple intravenous injections of gadolinium-based contrast agents. Acta Radiol 2016;57:389-91. [PMID: 26792824 DOI: 10.1177/0284185115626479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
438 Lock LL, Li Y, Mao X, Chen H, Staedtke V, Bai R, Ma W, Lin R, Li Y, Liu G, Cui H. One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging Agents. ACS Nano 2017;11:797-805. [PMID: 28075559 DOI: 10.1021/acsnano.6b07196] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 15.8] [Reference Citation Analysis]
439 Pinto SM, Tomé V, Calvete MJ, Castro MMC, Tóth É, Geraldes CF. Metal-based redox-responsive MRI contrast agents. Coordination Chemistry Reviews 2019;390:1-31. [DOI: 10.1016/j.ccr.2019.03.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
440 Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med 2012;27:1697-703. [PMID: 22692632 DOI: 10.1007/s11606-012-2098-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
441 Boyd AS, Sanyal S, Abraham JL. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? J Am Acad Dermatol 2010;62:337-42. [PMID: 19939504 DOI: 10.1016/j.jaad.2009.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
442 Linfert DR, Schell JO, Fine DM. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future: TREATMENT OF NSF. Seminars in Dialysis 2008;21:155-9. [DOI: 10.1111/j.1525-139x.2007.00407.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
443 Xie J, Haeckel A, Hauptmann R, Ray IP, Limberg C, Kulak N, Hamm B, Schellenberger E. Iron(III)-tCDTA derivatives as MRI contrast agents: Increased T1 relaxivities at higher magnetic field strength and pH sensing. Magn Reson Med 2021;85:3370-82. [PMID: 33538352 DOI: 10.1002/mrm.28664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
444 Li J, Zhuang Z, Jiang B, Zhao P, Lin C. Advances and perspectives in nanoprobes for noninvasive lymph node mapping. Nanomedicine 2015;10:1019-36. [DOI: 10.2217/nnm.14.201] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
445 Tranvinh E, Heit JJ, Hacein-Bey L, Provenzale J, Wintermark M. Contemporary Imaging of Cerebral Arteriovenous Malformations. AJR Am J Roentgenol 2017;208:1320-30. [PMID: 28267351 DOI: 10.2214/AJR.16.17306] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
446 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
447 Kadiyala D, Roer DA, Perazella MA. Nephrogenic Systemic Fibrosis Associated With Gadoversetamide Exposure: Treatment With Sodium Thiosulfate. American Journal of Kidney Diseases 2009;53:133-7. [DOI: 10.1053/j.ajkd.2008.09.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
448 Shin K, Granter SR, Coblyn JS, Gupta S. Progressive arm and leg stiffness in a patient with chronic renal impairment. Nat Rev Rheumatol 2008;4:557-62. [DOI: 10.1038/ncprheum0883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
449 Bauman G, Lützen U, Ullrich M, Gaass T, Dinkel J, Elke G, Meybohm P, Frerichs I, Hoffmann B, Borggrefe J, Knuth HC, Schupp J, Prüm H, Eichinger M, Puderbach M, Biederer J, Hintze C. Pulmonary functional imaging: qualitative comparison of Fourier decomposition MR imaging with SPECT/CT in porcine lung. Radiology 2011;260:551-9. [PMID: 21586678 DOI: 10.1148/radiol.11102313] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 8.5] [Reference Citation Analysis]
450 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
451 Gou BD, Bian S, Zhang TL, Wang K. Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages. Toxicol In Vitro 2010;24:1743-9. [PMID: 20471468 DOI: 10.1016/j.tiv.2010.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
452 Sammet S. Magnetic resonance safety. Abdom Radiol (NY) 2016;41:444-51. [PMID: 26940331 DOI: 10.1007/s00261-016-0680-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
453 Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008;190:1069-75. [PMID: 18356457 DOI: 10.2214/AJR.07.2884] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
454 Martin DR. Nephrogenic systemic fibrosis. Pediatr Radiol. 2008;38 Suppl 1:S125-S129. [PMID: 15168803 DOI: 10.1007/s00247-007-0589-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
455 Vignaux O, Deux J, Chabrillat Y, Willoteaux S, Marie P, Laurent F, Garot J. Les conditions techniques d’utilisation de l’IRM cardiaque. Journal de Radiologie 2009;90:1133-43. [DOI: 10.1016/s0221-0363(09)73260-3] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
456 Ramalho M, AlObaidy M, Busireddy KK, Altun E, Liu B, Semelka RC. Quantitative and qualitative comparison of 0.025 mmol/kg gadobenate dimeglumine for abdominal MRI at 1.5T and 3T MRI in patients with low estimated glomerular filtration rate. Eur J Radiol. 2015;84:26-32. [PMID: 25467229 DOI: 10.1016/j.ejrad.2014.10.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
457 Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. Clin J Am Soc Nephrol 2010;5:964-71. [PMID: 20299369 DOI: 10.2215/CJN.00140110] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
458 Chiribiri A, Kelle S, Götze S, Kriatselis C, Thouet T, Tangcharoen T, Paetsch I, Schnackenburg B, Fleck E, Nagel E. Visualization of the cardiac venous system using cardiac magnetic resonance. Am J Cardiol. 2008;101:407-412. [PMID: 18237610 DOI: 10.1016/j.amjcard.2007.08.049] [Cited by in Crossref: 58] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
459 Yamamoto Y, Tasaki Y, Kuwada Y, Ozawa Y, Inoue T. A preliminary report of breast cancer screening by positron emission mammography. Ann Nucl Med 2016;30:130-7. [PMID: 26586370 DOI: 10.1007/s12149-015-1040-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
460 Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. Radiology 2009;253:81-9. [DOI: 10.1148/radiol.2531082160] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
461 Fan Z, Sheehan J, Bi X, Liu X, Carr J, Li D. 3D noncontrast MR angiography of the distal lower extremities using flow-sensitive dephasing (FSD)-prepared balanced SSFP. Magn Reson Med 2009;62:1523-32. [PMID: 19877278 DOI: 10.1002/mrm.22142] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 8.2] [Reference Citation Analysis]
462 Di N, Cheng W, Chen H, Zhai F, Liu Y, Mu X, Chu Z, Lu N, Liu X, Wang B. Utility of arterial spin labelling MRI for discriminating atypical high-grade glioma from primary central nervous system lymphoma. Clin Radiol. 2019;74:165.e1-165.e9. [PMID: 30415766 DOI: 10.1016/j.crad.2018.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
463 Pereira RS, Gonul II, Mclaughlin K, Yilmaz S, Mahallati H. Assessment of Chronic Renal Allograft Nephropathy Using Contrast-Enhanced MRI: A Pilot Study. American Journal of Roentgenology 2010;194:W407-13. [DOI: 10.2214/ajr.09.2912] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
464 Lewis KG, Lester BW, Pan TD, Robinson-bostom L. Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 2006;33:695-700. [DOI: 10.1111/j.1600-0560.2006.00490.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
465 Huang XX, Jiang RH, Xu XQ, Zu QQ, Wu FY, Liu S, Shi HB. Ischemic Stroke Increased Gadolinium Deposition in the Brain and Aggravated Astrocyte Injury After Gadolinium-Based Contrast Agent Administration: Linear Versus Macrocyclic Agents. J Magn Reson Imaging 2021;53:1282-92. [PMID: 33555617 DOI: 10.1002/jmri.27407] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Hidaka F, Amano Y, Takahama K, Takagi R, Murakami R, Onozawa S, Kumita S. Assessment of renal impairment by non-contrast-enhanced conventional magnetic resonance imaging: comparison with 99mTc-DTPA renography. Jpn J Radiol 2011;29:378-85. [DOI: 10.1007/s11604-011-0567-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
467 Celiker FB, Tumkaya L, Mercantepe T, Beyazal M, Turan A, Beyazal Polat H, Suzan ZT, Inecikli MF, Akyildiz K, Yilmaz A. Effects of Gadodiamide and Gadoteric Acid on Rat Kidneys: A Comparative Study: Effects of Gadodiamide and Gadoteric Acid. J Magn Reson Imaging 2019;49:382-9. [DOI: 10.1002/jmri.26266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
468 Kindberg GM, Uran S, Friisk G, Martinsen I, Skotland T. The fate of Gd and chelate following intravenous injection of gadodiamide in rats. Eur Radiol 2010;20:1636-43. [PMID: 20157815 DOI: 10.1007/s00330-010-1716-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
469 Voskrebenzev A, Gutberlet M, Kaireit TF, Wacker F, Vogel-claussen J. Low-pass imaging of dynamic acquisitions (LIDA) with a group-oriented registration (GOREG) for proton MR imaging of lung ventilation: LIDA With a GOREG for Proton MRI of Lung Ventilation. Magn Reson Med 2017;78:1496-505. [DOI: 10.1002/mrm.26526] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
470 Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816. [PMID: 18710976 DOI: 10.1148/radiol.2483071863] [Cited by in Crossref: 226] [Cited by in F6Publishing: 161] [Article Influence: 17.4] [Reference Citation Analysis]
471 Baidya Kayal E, Kandasamy D, Sharma R, Sharma MC, Bakhshi S, Mehndiratta A. SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging. Eur Radiol 2020;30:3125-36. [PMID: 32086578 DOI: 10.1007/s00330-019-06647-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12. [DOI: 10.1002/jmri.21769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
473 Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH, Cho SH. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology. 2012;264:414-422. [PMID: 22550309 DOI: 10.1148/radiol.12112025] [Cited by in Crossref: 163] [Cited by in F6Publishing: 129] [Article Influence: 18.1] [Reference Citation Analysis]
474 Crane JK. Metal Nanoparticles in Infection and Immunity. Immunol Invest 2020;49:794-807. [PMID: 32524902 DOI: 10.1080/08820139.2020.1776724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
475 Li J, Jiang X, Shang L, Li Z, Yang C, Luo Y, Hu D, Shen Y, Zhang Z. L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent. Drug Deliv 2021;28:134-43. [PMID: 33356629 DOI: 10.1080/10717544.2020.1862363] [Reference Citation Analysis]
476 Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2011;64:91-6. [DOI: 10.1016/j.jaad.2009.12.044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
477 Zhu DY, Lu B, Yin JH, Ke QF, Xu H, Zhang CQ, Guo YP, Gao YS. Gadolinium-doped bioglass scaffolds promote osteogenic differentiation of hBMSC via the Akt/GSK3β pathway and facilitate bone repair in vivo. Int J Nanomedicine 2019;14:1085-100. [PMID: 30804672 DOI: 10.2147/IJN.S193576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 6.5] [Reference Citation Analysis]
478 Liu F, He X, Lei Z, Liu L, Zhang J, You H, Zhang H, Wang Z. Facile Preparation of Doxorubicin-Loaded Upconversion@Polydopamine Nanoplatforms for Simultaneous In Vivo Multimodality Imaging and Chemophotothermal Synergistic Therapy. Adv Healthcare Mater 2015;4:559-68. [DOI: 10.1002/adhm.201400676] [Cited by in Crossref: 120] [Cited by in F6Publishing: 105] [Article Influence: 17.1] [Reference Citation Analysis]
479 Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011;260:105-11. [PMID: 21586680 DOI: 10.1148/radiol.11102340] [Cited by in Crossref: 113] [Cited by in F6Publishing: 82] [Article Influence: 11.3] [Reference Citation Analysis]
480 Zhou Z, Chen H, Lipowska M, Wang L, Yu Q, Yang X, Tiwari D, Yang L, Mao H. A dual-modal magnetic nanoparticle probe for preoperative and intraoperative mapping of sentinel lymph nodes by magnetic resonance and near infrared fluorescence imaging. J Biomater Appl 2013;28:100-11. [PMID: 23812946 DOI: 10.1177/0885328212437883] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
481 Sigovan M, Gasper W, Alley HF, Owens CD, Saloner D. USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 2012;265:584-90. [PMID: 22875796 DOI: 10.1148/radiol.12112694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
482 Weems AC, Szafron JM, Easley AD, Herting S, Smolen J, Maitland DJ. Shape memory polymers with enhanced visibility for magnetic resonance- and X-ray imaging modalities. Acta Biomater 2017;54:45-57. [PMID: 28259837 DOI: 10.1016/j.actbio.2017.02.045] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
483 Morris JM, Miller GM. Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall. AJNR Am J Neuroradiol 2007;28:1964-7. [PMID: 17893215 DOI: 10.3174/ajnr.A0694] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
484 Verma SK, Mitchell DG, Yang R, Roth CG, O’kane P, Verma M, Parker L. Exophytic Renal Masses: Angular Interface with Renal Parenchyma for Distinguishing Benign from Malignant Lesions at MR Imaging. Radiology 2010;255:501-7. [DOI: 10.1148/radiol.09091109] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
485 Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2012;199:W17-W23. [PMID: 22733927 DOI: 10.2214/ajr.11.8144] [Cited by in Crossref: 78] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
486 Piscatelli JA, Ban J, Lucas AT, Zamboni WC. Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems. Pharmaceutics 2021;13:114. [PMID: 33477395 DOI: 10.3390/pharmaceutics13010114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
487 Botár R, Molnár E, Trencsényi G, Kiss J, Kálmán FK, Tircsó G. Stable and Inert Mn(II)-Based and pH-Responsive Contrast Agents. J Am Chem Soc 2020;142:1662-6. [DOI: 10.1021/jacs.9b09407] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 26.0] [Reference Citation Analysis]
488 Bueschen AJ, Lockhart ME. Evolution of urological imaging: Urological imaging. International Journal of Urology 2011;18:102-12. [DOI: 10.1111/j.1442-2042.2010.02677.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
489 Chrysochou C, Kalra PA. ATHEROMATOUS RENOVASCULAR DISEASE: OVERVIEW AND CHALLENGES. Journal of Renal Care 2008;34:179-90. [DOI: 10.1111/j.1755-6686.2008.00043.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
490 Sena BF, Stern JP, Pandharipande PV, Klemm B, Bulman J, Pedrosa I, Rofsky NM. Screening Patients to Assess Renal Function Before Administering Gadolinium Chelates: Assessment of the Choyke Questionnaire. American Journal of Roentgenology 2010;195:424-8. [DOI: 10.2214/ajr.09.3803] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
491 Christie A, Roditi G. Vascular imaging: the evolving role of the multidisciplinary team meeting in peripheral vascular disease. Semin Intervent Radiol 2014;31:320-9. [PMID: 25435657 DOI: 10.1055/s-0034-1393968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
492 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
493 McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology. 2015;275:772-782. [PMID: 25742194 DOI: 10.1148/radiol.15150025] [Cited by in Crossref: 827] [Cited by in F6Publishing: 665] [Article Influence: 137.8] [Reference Citation Analysis]
494 So K, Macquillan GC, Adams LA, Delriviere L, Mitchell A, Moody H, Wood DJ, Junckerstorff RC, Jeffrey GP. Malignant fibrous histiocytoma complicating nephrogenic systemic fibrosis post liver transplantation. Intern Med J. 2009;39:613-617. [PMID: 19769682 DOI: 10.1111/j.1445-5994.2009.01977.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
495 Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M. Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. Invest Radiol 2016;51:661-5. [DOI: 10.1097/rli.0000000000000318] [Cited by in Crossref: 52] [Cited by in F6Publishing: 16] [Article Influence: 10.4] [Reference Citation Analysis]
496 High WA. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Expert Review of Dermatology 2014;2:593-605. [DOI: 10.1586/17469872.2.5.593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
497 Hope TA, Leboit PE, High WA, Fu Y, Brasch RC. Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. Magnetic Resonance Imaging 2013;31:139-44. [DOI: 10.1016/j.mri.2012.06.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
498 Solmaz V, Köse Özlece H, Fatih Bozkurt M, Özkul B, Erbaş O. Repeated gadoteric acid and gadobutrol exposure causes deterioration of behavior and memory functions in rats: MRI, histopathological and biochemical evidence. Brain Res 2021;1754:147256. [PMID: 33422532 DOI: 10.1016/j.brainres.2020.147256] [Reference Citation Analysis]
499 Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Investigative Radiology 2007;42:139-45. [DOI: 10.1097/01.rli.0000253505.88945.d5] [Cited by in Crossref: 178] [Cited by in F6Publishing: 141] [Article Influence: 12.7] [Reference Citation Analysis]
500 Biglands JD, Radjenovic A, Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: Part II. J Cardiovasc Magn Reson. 2012;14:66. [PMID: 22995744 DOI: 10.1186/1532-429x-14-66] [Cited by in Crossref: 51] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
501 Rajca A, Wang Y, Boska M, Paletta JT, Olankitwanit A, Swanson MA, Mitchell DG, Eaton SS, Eaton GR, Rajca S. Organic radical contrast agents for magnetic resonance imaging. J Am Chem Soc 2012;134:15724-7. [PMID: 22974177 DOI: 10.1021/ja3079829] [Cited by in Crossref: 121] [Cited by in F6Publishing: 90] [Article Influence: 13.4] [Reference Citation Analysis]
502 Dehoratius DM, Cowper SE. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients: NEPHROGENIC SYSTEMIC FIBROSIS. Seminars in Dialysis 2006;19:191-4. [DOI: 10.1111/j.1525-139x.2006.00152.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
503 Corbin BA, Pollard AC, Allen MJ, Pagel MD. Summary of Imaging in 2020: Visualizing the Future of Healthcare with MR Imaging. Mol Imaging Biol 2019;21:193-9. [PMID: 30680525 DOI: 10.1007/s11307-019-01315-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
504 Klee D, Lanzman RS, Blondin D, Schmitt P, Oh J, Salgin B, Mayatepek E, Antoch G, Schaper J. Non-enhanced ECG-gated respiratory-triggered 3-D steady-state free-precession MR angiography with slab-selective inversion: initial experience in visualisation of renal arteries in free-breathing children without renal artery abnormality. Pediatr Radiol 2012;42:785-90. [DOI: 10.1007/s00247-011-2343-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
505 Prasad SR, Jagirdar J. Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy: A Primer for Radiologists. Journal of Computer Assisted Tomography 2008;32:1-3. [DOI: 10.1097/rct.0b013e31805d08ee] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
506 Leung N, Shaikh A, Cosio FG, Griffin MD, Textor SC, Gloor JM, Schwab TR, Larson TS, Dean PG, Prieto M, Nyberg SL, Stegall MD, Lee CU, Pittelkow MR. The Outcome of Patients with Nephrogenic Systemic Fibrosis after Successful Kidney Transplantation. American Journal of Transplantation 2010;10:558-62. [DOI: 10.1111/j.1600-6143.2009.02959.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
507 Semelka RC, Ramalho M, Alobaidy M, Ramalho J. Gadolinium in Humans: A Family of Disorders. American Journal of Roentgenology 2016;207:229-33. [DOI: 10.2214/ajr.15.15842] [Cited by in Crossref: 62] [Cited by in F6Publishing: 15] [Article Influence: 12.4] [Reference Citation Analysis]
508 Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014;65:96-105. [PMID: 24559602 DOI: 10.1016/j.carj.2012.11.002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 67] [Article Influence: 12.4] [Reference Citation Analysis]
509 Misra S, Thatipelli MR, Howe PW, Hunt C, Mathew V, Barsness GW, Pflueger A, Textor SC, Bjarnason H, Mckusick MA. Preliminary Study of the Use of Drug-eluting Stents in Atherosclerotic Renal Artery Stenoses 4 mm in Diameter or Smaller. Journal of Vascular and Interventional Radiology 2008;19:833-9. [DOI: 10.1016/j.jvir.2008.03.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
510 Roditi G, Kusumawidjaja D. Magnetic resonance angiography and computed tomography angiography for peripheral arterial disease. Imaging 2009;21:85-108. [DOI: 10.1259/imaging/55671114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
511 Gräfe JL, McNeill FE, Noseworthy MD, Chettle DR. Gadolinium detection via in vivo prompt gamma neutron activation analysis following gadolinium-based contrast agent injection: a pilot study in 10 human participants. Physiol Meas 2014;35:1861-72. [PMID: 25154504 DOI: 10.1088/0967-3334/35/9/1861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
512 Sun L, Wang Y, Yan C. Paradigms and Challenges for Bioapplication of Rare Earth Upconversion Luminescent Nanoparticles: Small Size and Tunable Emission/Excitation Spectra. Acc Chem Res 2014;47:1001-9. [DOI: 10.1021/ar400218t] [Cited by in Crossref: 267] [Cited by in F6Publishing: 192] [Article Influence: 38.1] [Reference Citation Analysis]
513 Gallo CJR, Mammarappallil JG, Johnson DY, Chalian H, Ronald J, Bashir MR, Kim CY. Ferumoxytol-enhanced MR Venography of the Central Veins of the Thorax for the Evaluation of Stenosis and Occlusion in Patients with Renal Impairment. Radiol Cardiothorac Imaging 2020;2:e200339. [PMID: 33778639 DOI: 10.1148/ryct.2020200339] [Reference Citation Analysis]
514 Knoepp F, Bettmer J, Fronius M. Gadolinium released by the linear gadolinium-based contrast-agent Gd-DTPA decreases the activity of human epithelial Na+ channels (ENaCs). Biochim Biophys Acta Biomembr 2017;1859:1040-8. [PMID: 28257815 DOI: 10.1016/j.bbamem.2017.02.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
515 Nguyen KL, Moriarty JM, Plotnik AN, Aksoy O, Yoshida T, Shemin RJ, Suh WM, Finn JP. Ferumoxytol-enhanced MR Angiography for Vascular Access Mapping before Transcatheter Aortic Valve Replacement in Patients with Renal Impairment: A Step Toward Patient-specific Care. Radiology 2018;286:326-37. [PMID: 29040038 DOI: 10.1148/radiol.2017162899] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
516 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
517 Acar T, Kaya E, Yoruk MD, Duzenli N, Senturk RS, Can C, Ozturk L, Tomruk C, Uyanikgil Y, Rybicki FJ. Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents. Jpn J Radiol 2019;37:458-65. [PMID: 30929137 DOI: 10.1007/s11604-019-00835-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
518 Luhar A, Khan S, Finn JP, Ghahremani S, Griggs R, Zaritsky J, Salusky I, Hall TR. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol 2016;46:1332-40. [PMID: 27059620 DOI: 10.1007/s00247-016-3605-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
519 Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine 2008;3:201-13. [DOI: 10.2217/17435889.3.2.201] [Cited by in Crossref: 185] [Cited by in F6Publishing: 116] [Article Influence: 14.2] [Reference Citation Analysis]
520 Soikkeli M, Kettunen MI, Nivajärvi R, Olsson V, Rönkkö S, Laakkonen JP, Lehto VP, Kavakka J, Heikkinen S. Assessment of the Relaxation-Enhancing Properties of a Nitroxide-Based Contrast Agent TEEPO-Glc with In Vivo Magnetic Resonance Imaging. Contrast Media Mol Imaging 2019;2019:5629597. [PMID: 31920468 DOI: 10.1155/2019/5629597] [Reference Citation Analysis]
521 Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47:855-69, vii. [PMID: 19744600 DOI: 10.1016/j.rcl.2009.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
522 Kramer U, Fenchel M, Laub G, Seeger A, Klumpp B, Bretschneider C, Finn JP, Claussen CD, Miller S. Low-Dose, Time-Resolved, Contrast-Enhanced 3D MR Angiography in the Assessment of the Abdominal Aorta and Its Major Branches at 3 Tesla. Academic Radiology 2010;17:564-76. [DOI: 10.1016/j.acra.2009.12.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
523 Gupta A, Shamseddin MK, Khaira A. Pathomechanisms of nephrogenic systemic fibrosis: new insights. Clin Exp Dermatol 2011;36:763-8. [PMID: 21790732 DOI: 10.1111/j.1365-2230.2011.04136.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
524 Edward M, Fitzgerald L, Thind C, Leman J, Burden AD. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol 2007;156:473-9. [PMID: 17300236 DOI: 10.1111/j.1365-2133.2006.07652.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
525 Thomson PC, Collidge TA, Mark PB, Traynor JP. Gadolinium contrast may be risky in kidney disease. BMJ 2007;334:1335-6. [PMID: 17599982 DOI: 10.1136/bmj.39254.924641.1F] [Reference Citation Analysis]
526 Lisjak D, Plohl O, Ponikvar-svet M, Majaron B. Dissolution of upconverting fluoride nanoparticles in aqueous suspensions. RSC Adv 2015;5:27393-7. [DOI: 10.1039/c5ra00902b] [Cited by in Crossref: 32] [Article Influence: 5.3] [Reference Citation Analysis]
527 Meloni A, Montanaro D, De Marchi D, Resta M, Keilberg P, Pistoia L, Positano V, Spasiano A, Casini T, De Bari CC, De Cori S, Pepe A. Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance. Clin Neuroradiol 2021;31:347-55. [PMID: 32185401 DOI: 10.1007/s00062-020-00897-z] [Reference Citation Analysis]
528 Jinzaki M, Kitagawa K, Tsai IC, Chan C, Yu W, Yong HS, Choi BW; ASCI CCT & CMR Guideline Working Group. ASCI 2010 contrast media guideline for cardiac imaging: a report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group. Int J Cardiovasc Imaging 2010;26:203-12. [PMID: 20931289 DOI: 10.1007/s10554-010-9691-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
529 Madhavan K, Chieng LO, Armstrong VL, Wang MY. Spondylodiscitis in end-stage renal disease: a systematic review. Journal of Neurosurgery: Spine 2019;30:674-82. [DOI: 10.3171/2018.9.spine18824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
530 Costelloe CM, Murphy WA Jr, Haygood TM, Kumar R, McEnery KW, Stafford RJ, Roy A, Bassett RL Jr, Harrell RK, Madewell JE. Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors. Skeletal Radiol 2011;40:327-33. [PMID: 20862469 DOI: 10.1007/s00256-010-1028-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
531 Islam MK, Kim S, Kim HK, Park S, Lee GH, Kang HJ, Jung JC, Park JS, Kim TJ, Chang Y. Manganese Complex of Ethylenediaminetetraacetic Acid (EDTA)-Benzothiazole Aniline (BTA) Conjugate as a Potential Liver-Targeting MRI Contrast Agent. J Med Chem 2017;60:2993-3001. [PMID: 28301142 DOI: 10.1021/acs.jmedchem.6b01799] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
532 Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 2008;58:1025-30. [PMID: 18485985 DOI: 10.1016/j.jaad.2008.02.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
533 Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425-2432. [PMID: 17711550 DOI: 10.1111/j.1600-6143.2007.01941.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
534 Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009;53:129-32. [PMID: 19012999 DOI: 10.1053/j.ajkd.2008.08.029] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
535 Latus J, Goffin E, Schroeder JA, Fritz P, Ott G, Ulmer C, Steurer W, Kimmel M, Biegger D, Segerer S, Alscher MD, Braun N. Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis. Perit Dial Int 2014;34:561-5. [PMID: 25075001 DOI: 10.3747/pdi.2013.00137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
536 Murphy DJ, Kwong RY. Contrast Agents in Cardiovascular Magnetic Resonance Imaging. In: Kwong RY, Jerosch-herold M, Heydari B, editors. Cardiovascular Magnetic Resonance Imaging. New York: Springer; 2019. pp. 127-43. [DOI: 10.1007/978-1-4939-8841-9_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
537 Lim RP, Koktzoglou I. Noncontrast magnetic resonance angiography: concepts and clinical applications. Radiol Clin North Am 2015;53:457-76. [PMID: 25953284 DOI: 10.1016/j.rcl.2014.12.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
538 Kogure T, Kogure K, Iizuka M, Ino A, Ishii M. Effective use of flow-spoiled FBI and time-SLIP methods in the diagnostic study of an aberrant vessel of the head and neck: "left jugular venous steal by the right jugular vein". J Magn Reson Imaging 2010;32:429-33. [PMID: 20677273 DOI: 10.1002/jmri.22273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
539 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
540 Tipirneni-Sajja A, Loeffler RB, Oesingmann N, Bissler J, Song R, McCarville B, Jones DP, Hudson M, Spunt SL, Hillenbrand CM. Measurement of glomerular filtration rate by dynamic contrast-enhanced magnetic resonance imaging using a subject-specific two-compartment model. Physiol Rep 2016;4:e12755. [PMID: 27081161 DOI: 10.14814/phy2.12755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
541 Lord M, Mcneill F, Gräfe J, Noseworthy M, Chettle D. A phantom-based feasibility study for detection of gadolinium in bone in-vivo using X-ray fluorescence. Applied Radiation and Isotopes 2016;112:103-9. [DOI: 10.1016/j.apradiso.2016.03.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
542 Voth M, Haneder S, Huck K, Gutfleisch A, Schönberg SO, Michaely HJ. Peripheral Magnetic Resonance Angiography With Continuous Table Movement in Combination With High Spatial and Temporal Resolution Time-Resolved MRA With a Total Single Dose (0.1 mmol/kg) of Gadobutrol at 3.0 T: . Investigative Radiology 2009;44:627-33. [DOI: 10.1097/rli.0b013e3181b4c26c] [Cited by in Crossref: 49] [Cited by in F6Publishing: 13] [Article Influence: 4.1] [Reference Citation Analysis]
543 Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015;41:884-898. [PMID: 24974785 DOI: 10.1002/jmri.24691] [Cited by in Crossref: 211] [Cited by in F6Publishing: 175] [Article Influence: 30.1] [Reference Citation Analysis]
544 Nong Q, Chen X, Hu L, Huang Y, Luan T, Liu H, Chen B. Identification and characterization of Gd-binding proteins in NIH-3T3 cells. Talanta 2020;219:121281. [DOI: 10.1016/j.talanta.2020.121281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
545 Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009;193:1044-1052. [PMID: 19770328 DOI: 10.2214/ajr.08.1461] [Cited by in Crossref: 137] [Cited by in F6Publishing: 43] [Article Influence: 11.4] [Reference Citation Analysis]
546 Trapasso G, Chiesa S, Freitas R, Pereira E. What do we know about the ecotoxicological implications of the rare earth element gadolinium in aquatic ecosystems? Sci Total Environ 2021;781:146273. [PMID: 33813143 DOI: 10.1016/j.scitotenv.2021.146273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
547 Chiu DY, Green D, Abidin N, Sinha S, Kalra PA. Cardiac imaging in patients with chronic kidney disease. Nat Rev Nephrol 2015;11:207-20. [PMID: 25561081 DOI: 10.1038/nrneph.2014.243] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
548 Maripuri S, Johansen KL. Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease—Is Zero Good Enough? JAMA Intern Med 2020;180:230. [DOI: 10.1001/jamainternmed.2019.5278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
549 Blankholm AD, Pedersen BG, Stausbøl-grøn B, Andersen G, Hørlyck A, Østrat EØ, Laustsen S, Ringgaard S. Preoperative planning of renal transplantation: a comparison of non-contrast-enhanced ultrasonography, computed tomography, and magnetic resonance angiography with observations from surgery. Acta Radiol 2015;56:1527-33. [DOI: 10.1177/0284185114562227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
550 Deng AC, Bilu DM, Sina B, Gaspari A. Localized nephrogenic fibrosing dermopathy: Aberrant dermal repairing? Journal of the American Academy of Dermatology 2008;58:336-9. [DOI: 10.1016/j.jaad.2007.10.491] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
551 Wilson GJ, Maki JH. Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. Magn Reson Imaging Clin N Am 2009;17:13-27. [PMID: 19364597 DOI: 10.1016/j.mric.2009.01.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
552 Leyendecker JR, Clingan MJ. Magnetic Resonance Urography Update—Are We There Yet? Seminars in Ultrasound, CT and MRI 2009;30:246-57. [DOI: 10.1053/j.sult.2009.03.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
553 Sigurdsson U, Müller G, Siversson C, Lammentausta E, Svensson J, Tiderius CJ, Dahlberg LE. Delayed gadolinium-enhanced MRI of meniscus (dGEMRIM) and cartilage (dGEMRIC) in healthy knees and in knees with different stages of meniscus pathology. BMC Musculoskelet Disord 2016;17:406. [PMID: 27682996 DOI: 10.1186/s12891-016-1244-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
554 Layne KA, Raja K, Dargan PI, Wood DM. Gadolinium Concentrations in Biological Matrices From Patients Exposed to Gadolinium-Based Contrast Agents. Invest Radiol 2021;56:458-64. [PMID: 34086014 DOI: 10.1097/RLI.0000000000000762] [Reference Citation Analysis]
555 Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2007;22:1395. [PMID: 17180360 DOI: 10.1007/s00467-006-0384-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
556 Elmholdt TR, Olesen AB, Jørgensen B, Kvist S, Skov L, Thomsen HS, Marckmann P, Pedersen M. Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. PLoS One 2013;8:e82037. [PMID: 24349178 DOI: 10.1371/journal.pone.0082037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
557 Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007;26:1190-7. [PMID: 17969161 DOI: 10.1002/jmri.21135] [Cited by in Crossref: 186] [Cited by in F6Publishing: 142] [Article Influence: 14.3] [Reference Citation Analysis]
558 Li B, Gong T, Xu N, Cui F, Yuan B, Yuan Q, Sun H, Wang L, Liu J. Improved Stability and Photothermal Performance of Polydopamine-Modified Fe3 O4 Nanocomposites for Highly Efficient Magnetic Resonance Imaging-Guided Photothermal Therapy. Small 2020;16:e2003969. [PMID: 33053265 DOI: 10.1002/smll.202003969] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
559 Vanasschen C, Molnár E, Tircsó G, Kálmán FK, Tóth É, Brandt M, Coenen HH, Neumaier B. Novel CDTA-based, Bifunctional Chelators for Stable and Inert Mn II Complexation: Synthesis and Physicochemical Characterization. Inorg Chem 2017;56:7746-60. [DOI: 10.1021/acs.inorgchem.7b00460] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
560 Courant T, Roullin VG, Cadiou C, Callewaert M, Andry MC, Portefaix C, Hoeffel C, de Goltstein MC, Port M, Laurent S, Elst LV, Muller R, Molinari M, Chuburu F. Hydrogels Incorporating GdDOTA: Towards Highly Efficient Dual T1/T2 MRI Contrast Agents. Angew Chem 2012;124:9253-6. [DOI: 10.1002/ange.201203190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
561 Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. Nat Biotechnol 2014;32:804-18. [PMID: 25093889 DOI: 10.1038/nbt.2993] [Cited by in Crossref: 154] [Cited by in F6Publishing: 137] [Article Influence: 25.7] [Reference Citation Analysis]
562 Hedley AJ, Molan MP, Hare DL, Anavekar NS, Ierino FL. NEPHROGENIC SYSTEMIC FIBROSIS ASSOCIATED WITH GADOLINIUM-CONTAINING CONTRAST MEDIA ADMINISTRATION IN PATIENTS WITH REDUCED GLOMERULAR FILTRATION RATE. Nephrology 2007;12:111-111. [DOI: 10.1111/j.1440-1797.2006.00751.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
563 Lenkinski RE. Gadolinium Retention and Deposition Revisited: How the Chemical Properties of Gadolinium-based Contrast Agents and the Use of Animal Models Inform Us about the Behavior of These Agents in the Human Brain. Radiology 2017;285:721-4. [DOI: 10.1148/radiol.2017172138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
564 Maurer M, Heine O, Wolf M, Durmus T, Wagner M, Hamm B. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol 2012;81:885-90. [PMID: 21555197 DOI: 10.1016/j.ejrad.2011.04.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
565 Clough TJ, Jiang L, Wong KL, Long NJ. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents. Nat Commun 2019;10:1420. [PMID: 30926784 DOI: 10.1038/s41467-019-09342-3] [Cited by in Crossref: 90] [Cited by in F6Publishing: 47] [Article Influence: 45.0] [Reference Citation Analysis]
566 Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60:1508-18. [PMID: 19404939 DOI: 10.1002/art.24471] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
567 Hoerr V, Faber C. Magnetic resonance imaging characterization of microbial infections. J Pharm Biomed Anal. 2014;93:136-146. [PMID: 24257444 DOI: 10.1016/j.jpba.2013.10.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
568 Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. [PMID: 18952698 DOI: 10.1093/ndt/gfn593] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
569 Miyamoto J, Tanikawa A, Igarashi A, Hataya H, Kobayashi K, Ikegami M, Sotome A, Nagai Y, Kameyama K, Ishiko A. Detection of iron deposition in dermal fibrocytes is a useful tool for histologic diagnosis of nephrogenic systemic fibrosis. Am J Dermatopathol 2011;33:271-6. [PMID: 21389836 DOI: 10.1097/DAD.0b013e3181f63eb1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
570 Saida T, Mori K, Sato F, Shindo M, Takahashi H, Takahashi N, Sakakibara Y, Minami M. Prospective intraindividual comparison of unenhanced magnetic resonance imaging vs contrast-enhanced computed tomography for the planning of endovascular abdominal aortic aneurysm repair. Journal of Vascular Surgery 2012;55:679-87. [DOI: 10.1016/j.jvs.2011.09.091] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
571 Bickham P, Golembiewski J. Contrast Media Use in the Operating Room. Journal of PeriAnesthesia Nursing 2010;25:94-103. [DOI: 10.1016/j.jopan.2010.01.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
572 Himmelreich U, Hoehn M. Stem cell labeling for magnetic resonance imaging. Minim Invasive Ther Allied Technol 2008;17:132-42. [PMID: 18465447 DOI: 10.1080/13645700801969873] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
573 Karcaaltincaba M, Oguz B, Haliloglu M. Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. Pediatr Radiol 2009;39 Suppl 3:382-4. [PMID: 19440757 DOI: 10.1007/s00247-009-1236-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
574 Maki JH, Wilson GJ, Eubank WB, Glickerman DJ, Millan JA, Hoogeveen RM. Navigator-Gated MR Angiography of the Renal Arteries: A Potential Screening Tool for Renal Artery Stenosis. American Journal of Roentgenology 2007;188:W540-6. [DOI: 10.2214/ajr.06.1138] [Cited by in Crossref: 48] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
575 Martin DR, Kalb B, Mittal A, Salman K, Vedantham S, Mittal PK. No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. Radiology 2018;286:113-9. [DOI: 10.1148/radiol.2017170102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
576 Kong Y, Zhang S, Wang J, Han C, Yu N, Liu Q, Wang W, Xu K. Potential toxicity evaluation and comparison within multiple mice organs after repeat injections of linear versus macrocyclic gadolinium-based contrast agents: A comprehensive and time course study. Toxicol Lett 2021;350:152-61. [PMID: 34311048 DOI: 10.1016/j.toxlet.2021.07.016] [Reference Citation Analysis]
577 Duffy KL, Green L, Harris R, Powell D. Treatment of nephrogenic systemic fibrosis with Re-PUVA. J Am Acad Dermatol 2008;59:S39-40. [PMID: 18625379 DOI: 10.1016/j.jaad.2007.08.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
578 Wáng YX, Idée JM. A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. Quant Imaging Med Surg 2017;7:88-122. [PMID: 28275562 DOI: 10.21037/qims.2017.02.09] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 26.0] [Reference Citation Analysis]
579 Bruckman MA, Yu X, Steinmetz NF. Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology 2013;24:462001. [PMID: 24158750 DOI: 10.1088/0957-4484/24/46/462001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
580 Miao Y, Xie F, Cen J, Zhou F, Tao X, Luo J, Han G, Kong X, Yang X, Sun J, Ling J. Fe 3+ @polyDOPA- b -polysarcosine, a T 1 -Weighted MRI Contrast Agent via Controlled NTA Polymerization. ACS Macro Lett 2018;7:693-8. [DOI: 10.1021/acsmacrolett.8b00287] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 8.7] [Reference Citation Analysis]
581 Chen WT, Liang JL, Chen MH, Liao CC, Huang TL, Chen TY, Tsang LL, Ou HY, Hsu HW, Lazo MZ. Noncontrast Magnetic Resonance Angiography Using Inflow Sensitive Inversion Recovery Technique for Vascular Evaluation in Pre-liver Transplantation Recipients. Transplant Proc. 2016;48:1032-1035. [PMID: 27320549 DOI: 10.1016/j.transproceed.2015.12.083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
582 Ramalho J, Ramalho M, Jay M, Burke LM, Semelka RC. Gadolinium toxicity and treatment. Magn Reson Imaging. 2016;34:1394-1398. [PMID: 27693607 DOI: 10.1016/j.mri.2016.09.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 12.2] [Reference Citation Analysis]
583 Öner AY, Barutcu B, Aykol Ş, Tali ET. Intrathecal Contrast-Enhanced Magnetic Resonance Imaging–Related Brain Signal Changes: Residual Gadolinium Deposition? Invest Radiol 2017;52:195-7. [DOI: 10.1097/rli.0000000000000327] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
584 Lim RP, Hecht EM, Desmond PM. Noncontrast Magnetic Resonance Angiography in the Era of Nephrogenic Systemic Fibrosis and Gadolinium Deposition. J Comput Assist Tomogr 2021;45:37-51. [PMID: 32976265 DOI: 10.1097/RCT.0000000000001074] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Hicks CW, Clark TWI, Cooper CJ, de Bhailis ÁM, De Carlo M, Green D, Małyszko J, Miglinas M, Textor SC, Herzog CA, Johansen KL, Reinecke H, Kalra PA. Artherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. Am J Kidney Dis 2021:S0272-6386(21)00776-9. [PMID: 34384806 DOI: 10.1053/j.ajkd.2021.06.025] [Reference Citation Analysis]
586 Zhang J, Fatouros PP, Shu C, Reid J, Owens LS, Cai T, Gibson HW, Long GL, Corwin FD, Chen ZJ, Dorn HC. High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality. Bioconjug Chem 2010;21:610-5. [PMID: 20218678 DOI: 10.1021/bc900375n] [Cited by in Crossref: 106] [Cited by in F6Publishing: 79] [Article Influence: 9.6] [Reference Citation Analysis]
587 Cordova KB, Oberg TJ, Malik M, Robinson-bostom L. Dermatologic Conditions Seen in End-Stage Renal Disease. Seminars in Dialysis 2009;22:45-55. [DOI: 10.1111/j.1525-139x.2008.00534.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
588 Sahni VA, Silverman SG. Imaging management of incidentally detected small renal masses. Semin Intervent Radiol 2014;31:9-19. [PMID: 24596435 DOI: 10.1055/s-0033-1363838] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
589 Edgar E, Woltjer R, Whitham R, Gultekin SH, Watnick S, Cupler EJ. Nephrogenic systemic fibrosis presenting as myopathy: A case report with histopathologic correlation. Neuromuscular Disorders 2010;20:411-3. [DOI: 10.1016/j.nmd.2010.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
590 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
591 Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'malley RB, Parsons DJ, Fuller ER, Semelka RC. Risk of Nephrogenic Systemic Fibrosis: Evaluation of Gadolinium Chelate Contrast Agents at Four American Universities. Radiology 2008;248:799-806. [DOI: 10.1148/radiol.2483072093] [Cited by in Crossref: 138] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
592 Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-870. [PMID: 17607298 DOI: 10.1038/labinvest.3700654] [Cited by in Crossref: 306] [Cited by in F6Publishing: 290] [Article Influence: 21.9] [Reference Citation Analysis]
593 Cameli M, Mandoli GE, Mondillo S. Left atrium: the last bulwark before overt heart failure. Heart Fail Rev 2017;22:123-31. [PMID: 27873135 DOI: 10.1007/s10741-016-9589-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
594 Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol 2015;30:515-21. [PMID: 25212105 DOI: 10.1007/s00467-014-2953-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
595 Strzeminska I, Factor C, Robert P, Grindel AL, Comby PO, Szpunar J, Corot C, Lobinski R. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents. Invest Radiol 2020;55:138-43. [PMID: 31917763 DOI: 10.1097/RLI.0000000000000623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
596 Thakral C, Abraham JL. Gadolinium-Induced Nephrogenic Systemic Fibrosis Is Associated with Insoluble Gd Deposits in Tissues: In Vivo Transmetallation Confirmed by Microanalysis. Journal of Cutaneous Pathology 2009;36:1244-54. [DOI: 10.1111/j.1600-0560.2009.01283.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
597 Kiviniemi A, Gardberg M, Ek P, Frantzén J, Bobacka J, Minn H. Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. Neuroradiology 2019;61:535-44. [DOI: 10.1007/s00234-019-02172-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
598 Nottelet B, Darcos V, Coudane J. Aliphatic polyesters for medical imaging and theranostic applications. European Journal of Pharmaceutics and Biopharmaceutics 2015;97:350-70. [DOI: 10.1016/j.ejpb.2015.06.023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
599 Salehi Ravesh M, Langguth P, Pfarr JA, Schupp J, Trentmann J, Koktzoglou I, Edelman RR, Graessner J, Greiser A, Hautemann D, Hennemuth A, Both M, Jansen O, Hövener JB, Schäfer JP. Non-contrast-enhanced magnetic resonance imaging for visualization and quantification of endovascular aortic prosthesis, their endoleaks and aneurysm sacs at 1.5 T. Magn Reson Imaging 2019;60:164-72. [PMID: 31075419 DOI: 10.1016/j.mri.2019.05.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
600 Pierre VC, Allen MJ, Caravan P. Contrast agents for MRI: 30+ years and where are we going? J Biol Inorg Chem 2014;19:127-31. [PMID: 24414380 DOI: 10.1007/s00775-013-1074-5] [Cited by in Crossref: 95] [Cited by in F6Publishing: 66] [Article Influence: 13.6] [Reference Citation Analysis]
601 Berger F, Kubik-huch RA, Niemann T, Schmid HR, Poetzsch M, Froehlich JM, Beer JH, Thali MJ, Kraemer T. Gadolinium Distribution in Cerebrospinal Fluid after Administration of a Gadolinium-based MR Contrast Agent in Humans. Radiology 2018;288:703-9. [DOI: 10.1148/radiol.2018171829] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
602 Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009;30:1335-40. [DOI: 10.1002/jmri.21976] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
603 Kiryu S, Dodanuki K, Takao H, Watanabe M, Inoue Y, Takazoe M, Sahara R, Unuma K, Ohtomo K. Free-breathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn's disease. J Magn Reson Imaging 2009;29:880-6. [PMID: 19306416 DOI: 10.1002/jmri.21725] [Cited by in Crossref: 150] [Cited by in F6Publishing: 119] [Article Influence: 12.5] [Reference Citation Analysis]
604 Thomsen HS. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Media. In: Thomsen HS, Webb JAW, editors. Contrast Media. Berlin: Springer Berlin Heidelberg; 2014. pp. 207-17. [DOI: 10.1007/174_2013_903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
605 Mansour M, Kamper L, Altenburg A, Haage P. Radiological Central Vein Treatment in Vascular Access. J Vasc Access 2008;9:85-101. [DOI: 10.1177/112972980800900203] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
606 Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Radiology 2009;250:371-7. [PMID: 19188312 DOI: 10.1148/radiol.2502080498] [Cited by in Crossref: 177] [Cited by in F6Publishing: 130] [Article Influence: 14.8] [Reference Citation Analysis]
607 Nortier JL, del Marmol V. Nephrogenic systemic fibrosis the need for a multidisciplinary approach. Nephrology Dialysis Transplantation 2007;22:3097-101. [DOI: 10.1093/ndt/gfm430] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
608 Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69:2024-33. [PMID: 20959327 DOI: 10.1136/ard.2010.134858] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
609 Motoyama D, Ishii Y, Takehara Y, Sugiyama M, Yang W, Nasu H, Ushio T, Hirose Y, Ohishi N, Wakayama T, Kabasawa H, Johnson K, Wieben O, Sakahara H, Ozono S. Four-dimensional phase-contrast vastly undersampled isotropic projection reconstruction (4D PC-VIPR) MR evaluation of the renal arteries in transplant recipients: Preliminary results: 4D PC-VIPR in Renal Graft Arteries. J Magn Reson Imaging 2017;46:595-603. [DOI: 10.1002/jmri.25607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
610 Wang YF, Sun LD, Xiao JW, Feng W, Zhou JC, Shen J, Yan CH. Rare-Earth nanoparticles with enhanced upconversion emission and suppressed rare-Earth-ion leakage. Chemistry 2012;18:5558-64. [PMID: 22488939 DOI: 10.1002/chem.201103485] [Cited by in Crossref: 167] [Cited by in F6Publishing: 133] [Article Influence: 18.6] [Reference Citation Analysis]
611 Lancelot E. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion. Invest Radiol 2016;51:691-700. [DOI: 10.1097/rli.0000000000000280] [Cited by in Crossref: 62] [Cited by in F6Publishing: 17] [Article Influence: 12.4] [Reference Citation Analysis]
612 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
613 Clément O, Faye N, Fournier L, Siauve N, Frija G. Rein et produits de contraste iodés et gadolinés. Journal de Radiologie 2011;92:291-8. [DOI: 10.1016/j.jradio.2011.02.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
614 Kielstein JT, Schiffer M. [Nephrogenic systemic fibrosis: a rare disease with grave consequences]. Internist (Berl) 2010;51:39-44. [PMID: 20033388 DOI: 10.1007/s00108-009-2408-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
615 Quatresooz P, Paquet P, Hermanns-Lê T, Piérard GE. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Appl Immunohistochem Mol Morphol 2010;18:448-52. [PMID: 20485155 DOI: 10.1097/PAI.0b013e3181de372e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
616 Payabvash S, Kajbafzadeh A, Saeedi P, Sadeghi Z, Elmi A, Mehdizadeh M. Application of magnetic resonance urography in diagnosis of congenital urogenital anomalies in children. Pediatr Surg Int 2008;24:979-86. [DOI: 10.1007/s00383-008-2196-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
617 Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis Rheum 2007;56:3173-5. [DOI: 10.1002/art.22926] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
618 Braun K, Dunsch L, Pipkorn R, Bock M, Baeuerle T, Yang S, Waldeck W, Wiessler M. Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnostics. Int J Med Sci 2010;7:136-46. [PMID: 20567614 DOI: 10.7150/ijms.7.136] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
619 Neto JA, Elazzazzi M, Altun E, Semelka RC. When should abdominal magnetic resonance imaging be used? Clin Gastroenterol Hepatol 2008;6:610-5. [PMID: 18550003 DOI: 10.1016/j.cgh.2008.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
620 Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C, Choukroun G, Deray G. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol. 2010;73:357-359. [PMID: 19128909 DOI: 10.1016/j.ejrad.2008.11.021] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
621 Fan Z, Hodnett PA, Davarpanah AH, Scanlon TG, Sheehan JJ, Varga J, Carr JC, Li D. Noncontrast magnetic resonance angiography of the hand: improved arterial conspicuity by multidirectional flow-sensitive dephasing magnetization preparation in 3D balanced steady-state free precession imaging. Invest Radiol 2011;46:515-23. [PMID: 21487301 DOI: 10.1097/RLI.0b013e318217daee] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
622 Jokerst JV, Khademi C, Gambhir SS. Intracellular aggregation of multimodal silica nanoparticles for ultrasound-guided stem cell implantation. Sci Transl Med 2013;5:177ra35. [PMID: 23515077 DOI: 10.1126/scitranslmed.3005228] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
623 Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619-2621. [PMID: 17061066 DOI: 10.1007/s00330-006-0495-8] [Cited by in Crossref: 261] [Cited by in F6Publishing: 191] [Article Influence: 17.4] [Reference Citation Analysis]
624 Weinreb JC, Kuo PH. Nephrogenic Systemic Fibrosis. Magnetic Resonance Imaging Clinics of North America 2009;17:159-67. [DOI: 10.1016/j.mric.2009.01.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
625 MacFarland DK, Walker KL, Lenk RP, Wilson SR, Kumar K, Kepley CL, Garbow JR. Hydrochalarones: a novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J Med Chem 2008;51:3681-3. [PMID: 18558670 DOI: 10.1021/jm800521j] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
626 Leyendecker JR, Barnes CE, Zagoria RJ. MR urography: techniques and clinical applications. Radiographics. 2008;28:23-46; discussion 46-47. [PMID: 18203929 DOI: 10.1148/rg.281075077] [Cited by in Crossref: 120] [Cited by in F6Publishing: 70] [Article Influence: 9.2] [Reference Citation Analysis]
627 Altun E, Martin DR, Wertman R, Lugo-somolinos A, Fuller ER, Semelka RC. Nephrogenic Systemic Fibrosis: Change in Incidence Following a Switch in Gadolinium Agents and Adoption of a Gadolinium Policy—Report from Two U.S. Universities. Radiology 2009;253:689-96. [DOI: 10.1148/radiol.2533090649] [Cited by in Crossref: 112] [Cited by in F6Publishing: 73] [Article Influence: 9.3] [Reference Citation Analysis]
628 Kariniemi J, Sequeiros RB, Ojala R, Tervonen O. MRI-guided percutaneous nephrostomy: a feasibility study. Eur Radiol 2009;19:1296-301. [DOI: 10.1007/s00330-008-1235-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
629 Attyé A, Troprès I, Rouchy R, Righini C, Espinoza S, Kastler A, Krainik A. Diffusion MRI: literature review in salivary gland tumors. Oral Dis 2017;23:572-5. [DOI: 10.1111/odi.12543] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
630 Lord ML, McNeill FE, Gräfe JL, Galusha AL, Parsons PJ, Noseworthy MD, Howard L, Chettle DR. Confirming improved detection of gadolinium in bone using in vivo XRF. Appl Radiat Isot 2017;120:111-8. [PMID: 27987464 DOI: 10.1016/j.apradiso.2016.12.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
631 Cho SB, Lee AL, Chang HW, Kim KA, Yoo WJ, Yeom JA, Rho MH, Kim SJ, Lim YJ, Han M. Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients. J Magn Reson Imaging 2020;51:861-8. [PMID: 31663202 DOI: 10.1002/jmri.26940] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
632 Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A. Gadolinium retention in the body: what we know and what we can do. Radiol med 2017;122:589-600. [DOI: 10.1007/s11547-017-0757-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
633 Choi J, Ha R, Wynn R. Nephrogenic Systemic Fibrosis on Mammography. Current Problems in Diagnostic Radiology 2015;44:517-20. [DOI: 10.1067/j.cpradiol.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
634 Weng TI, Chen HJ, Lu CW, Ho YC, Wu JL, Liu SH, Hsiao JK. Exposure of Macrophages to Low-Dose Gadolinium-Based Contrast Medium: Impact on Oxidative Stress and Cytokines Production. Contrast Media Mol Imaging 2018;2018:3535769. [PMID: 30627059 DOI: 10.1155/2018/3535769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
635 Lancelot E, Raynaud J, Desché P. Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. Invest Radiol 2020;55:578-88. [DOI: 10.1097/rli.0000000000000684] [Cited by in Crossref: 10] [Article Influence: 10.0] [Reference Citation Analysis]
636 Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007;2:199-205. [PMID: 17712863 DOI: 10.1002/cmmi.146] [Cited by in Crossref: 142] [Cited by in F6Publishing: 117] [Article Influence: 10.1] [Reference Citation Analysis]
637 Koktzoglou I, Edelman RR. STAR and STARFIRE for flow-dependent and flow-independent noncontrast carotid angiography: STAR and STARFIRE Carotid Angiography. Magn Reson Med 2009;61:117-24. [DOI: 10.1002/mrm.21769] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
638 Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA. Nephrogenic systemic fibrosis: A clinicopathologic study of six cases. Journal of the American Academy of Dermatology 2007;57:105-11. [DOI: 10.1016/j.jaad.2007.02.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
639 Rasschaert M, Idée JM, Robert P, Fretellier N, Vives V, Violas X, Ballet S, Corot C. Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats. Invest Radiol 2017;52:255-64. [PMID: 28067754 DOI: 10.1097/RLI.0000000000000339] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 8.8] [Reference Citation Analysis]
640 Coelho DH, Tang Y, Suddarth B, Mamdani M. MRI surveillance of vestibular schwannomas without contrast enhancement: Clinical and economic evaluation: Tumor Surveillance Without Contrast. The Laryngoscope 2018;128:202-9. [DOI: 10.1002/lary.26589] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
641 Sheehan JJ, Fan Z, Davarpanah AH, Hodnett PA, Varga J, Carr JC, Li D. Nonenhanced MR angiography of the hand with flow-sensitive dephasing-prepared balanced SSFP sequence: initial experience with systemic sclerosis. Radiology 2011;259:248-56. [PMID: 21330560 DOI: 10.1148/radiol.10100851] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
642 Wang H, Raghupathi KR, Zhuang J, Thayumanavan S. Activatable Dendritic 19F Probes for Enzyme Detection. ACS Macro Lett 2015;4:422-5. [PMID: 25949857 DOI: 10.1021/acsmacrolett.5b00199] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
643 Lövblad KO, Anzalone N, Dörfler A, Essig M, Hurwitz B, Kappos L, Lee SK, Filippi M. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31:983-9. [PMID: 20019103 DOI: 10.3174/ajnr.A1906] [Cited by in Crossref: 68] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
644 George V, Tammisetti VS, Surabhi VR, Shanbhogue AK. Chronic Fibrosing Conditions in Abdominal Imaging. RadioGraphics 2013;33:1053-80. [DOI: 10.1148/rg.334125081] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
645 Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, Swartz RD. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009;44:74-81. [PMID: 19077912 DOI: 10.1097/RLI.0b013e31818f76b5] [Cited by in Crossref: 66] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
646 Gauden AJ, Phal PM, Drummond KJ. MRI safety: nephrogenic systemic fibrosis and other risks. J Clin Neurosci 2010;17:1097-104. [PMID: 20542435 DOI: 10.1016/j.jocn.2010.01.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
647 Semelka RC, Prybylski JP, Ramalho M. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents. Magn Reson Imaging 2019;58:174-8. [PMID: 30471330 DOI: 10.1016/j.mri.2018.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
648 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
649 Alwasiyah D, Murphy C, Jannetto P, Hogg M, Beuhler MC. Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study. J Med Toxicol 2019;15:121-7. [PMID: 30543028 DOI: 10.1007/s13181-018-0693-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
650 Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 2010;10:133-45. [PMID: 20945944 DOI: 10.2165/11539140-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
651 Rozenfeld MN, Podberesky DJ. Gadolinium-based contrast agents in children. Pediatr Radiol 2018;48:1188-96. [DOI: 10.1007/s00247-018-4165-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
652 McGrogan DG, Maxwell AP, Khawaja AZ, Inston NG. Current tools for prediction of arteriovenous fistula outcomes. Clin Kidney J 2015;8:282-9. [PMID: 26034589 DOI: 10.1093/ckj/sfv019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
653 Kurban MS, Boueiz A, Kibbi AG. Cutaneous manifestations of chronic kidney disease. Clin Dermatol. 2008;26:255-264. [PMID: 18640522 DOI: 10.1016/j.clindermatol.2007.10.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
654 Gharagouzloo CA, McMahon PN, Sridhar S. Quantitative contrast-enhanced MRI with superparamagnetic nanoparticles using ultrashort time-to-echo pulse sequences. Magn Reson Med 2015;74:431-41. [PMID: 25168606 DOI: 10.1002/mrm.25426] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
655 Bryant B, Im K, Broome D. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clinical Radiology 2009;64:706-13. [DOI: 10.1016/j.crad.2009.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
656 Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 2013;183:796-807. [PMID: 23867799 DOI: 10.1016/j.ajpath.2013.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
657 Roditi G, Maki JH, Oliveira G, Michaely HJ. Renovascular imaging in the NSF Era. J Magn Reson Imaging. 2009;30:1323-1334. [PMID: 19937926 DOI: 10.1002/jmri.21977] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
658 Rigsby CK, McKenney SE, Hill KD, Chelliah A, Einstein AJ, Han BK, Robinson JD, Sammet CL, Slesnick TC, Frush DP. Radiation dose management for pediatric cardiac computed tomography: a report from the Image Gently 'Have-A-Heart' campaign. Pediatr Radiol 2018;48:5-20. [PMID: 29292481 DOI: 10.1007/s00247-017-3991-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
659 Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158:273-80. [PMID: 18067485 DOI: 10.1111/j.1365-2133.2007.08335.x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 127] [Article Influence: 10.9] [Reference Citation Analysis]
660 Gupta A, Stait-gardner T, de Campo L, Waddington LJ, Kirby N, Price WS, Moghaddam MJ. Nanoassemblies of Gd–DTPA–monooleyl and glycerol monooleate amphiphiles as potential MRI contrast agents. J Mater Chem B 2014;2:1225. [DOI: 10.1039/c3tb21069c] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
661 Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
662 Metzger GJ, Auerbach EJ, Akgun C, Simonson J, Bi X, Uğurbil K, van de Moortele PF. Dynamically applied B1+ shimming solutions for non-contrast enhanced renal angiography at 7.0 Tesla. Magn Reson Med 2013;69:114-26. [PMID: 22442056 DOI: 10.1002/mrm.24237] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
663 Smadja L, Rémy-Jardin M, Dupuis P, Deken-Delannoy V, Devos P, Duhamel A, Laffitte JJ, Dequiedt P, Rémy J. [Gadolinium-enhanced thoracic CTA: retrospective analysis of image quality and tolerability in 45 patients evaluated prior to the description of nephrogenic systemic fibrosis]. J Radiol 2009;90:287-98. [PMID: 19421113 DOI: 10.1016/s0221-0363(09)72507-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
664 Qian X, Han X, Yu L, Xu T, Chen Y. Manganese‐Based Functional Nanoplatforms: Nanosynthetic Construction, Physiochemical Property, and Theranostic Applicability. Adv Funct Mater 2019;30:1907066. [DOI: 10.1002/adfm.201907066] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
665 Le Goff S, Barrat JA, Chauvaud L, Paulet YM, Gueguen B, Ben Salem D. Compound-specific recording of gadolinium pollution in coastal waters by great scallops. Sci Rep 2019;9:8015. [PMID: 31142781 DOI: 10.1038/s41598-019-44539-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 8.5] [Reference Citation Analysis]
666 Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Rev Nephrol 2007;3:111-5. [DOI: 10.1038/ncpneph0373] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
667 Hao J, Bourrinet P, Desché P. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study): . Investigative Radiology 2019;54:396-402. [DOI: 10.1097/rli.0000000000000556] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
668 Raatschen HJ, Fu Y, Brasch RC, Pietsch H, Shames DM, Yeh BM. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 2009;44:265-70. [PMID: 19346961 DOI: 10.1097/RLI.0b013e31819f1b60] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
669 Cowell GW, Reid AW, Roditi GH. Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. Insights Imaging 2012;3:495-504. [PMID: 22865510 DOI: 10.1007/s13244-012-0188-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
670 Kálmán FK, Nagy V, Uzal-Varela R, Pérez-Lourido P, Esteban-Gómez D, Garda Z, Pota K, Mezei R, Pallier A, Tóth É, Platas-Iglesias C, Tircsó G. Expanding the Ligand Classes Used for Mn(II) Complexation: Oxa-aza Macrocycles Make the Difference. Molecules 2021;26:1524. [PMID: 33802241 DOI: 10.3390/molecules26061524] [Reference Citation Analysis]
671 Ringler MD, Rhodes NG, Ayers-Ringler JR, Jakaitis DR, McDonald RJ, Kallmes DF, McDonald JS. Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents. Skeletal Radiol 2021;50:1419-25. [PMID: 33404669 DOI: 10.1007/s00256-020-03695-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
672 Essig M, Anzalone N, Combs SE, Dörfler À, Lee SK, Picozzi P, Rovira A, Weller M, Law M. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol 2012;33:803-17. [PMID: 22016411 DOI: 10.3174/ajnr.A2640] [Cited by in Crossref: 66] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
673 Morita S, Kojima S, Hirata M, Suzuki M, Suzuki K, Masukawa A, Ueno E. Unenhanced ECG-gated fast spin-echo MR digital subtraction angiography (MRDSA) using short echo-spacing three-dimensional sequence of femoral arteries: Initial experience. J Magn Reson Imaging 2011;34:157-64. [DOI: 10.1002/jmri.22595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
674 Mrsic Z, Mousavi N, Hulten E, Bittencourt MS. The Prognostic Value of Late Gadolinium Enhancement in Nonischemic Heart Disease. Magnetic Resonance Imaging Clinics of North America 2019;27:545-61. [DOI: 10.1016/j.mric.2019.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
675 Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218-24. [PMID: 18538448 DOI: 10.1016/j.jaad.2008.04.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
676 Gianolio E, Gregorio ED, Aime S. Chemical Insights into the Issues of Gd Retention in the Brain and Other Tissues Upon the Administration of Gd-Containing MRI Contrast Agents: Chemical Insights into the Issues of Gd Retention in the Brain and Other Tissues Upon the Administration of Gd-Containing MRI Contrast Agents. Eur J Inorg Chem 2019;2019:137-51. [DOI: 10.1002/ejic.201801220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
677 Hynes BG, Margey RJ, Ruggiero N, Kiernan TJ, Rosenfield K, Jaff MR. Endovascular Management of Acute Limb Ischemia. Annals of Vascular Surgery 2012;26:110-24. [DOI: 10.1016/j.avsg.2011.05.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
678 [DOI: 10.1117/12.2078676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
679 Tasker F, Fleming H, Mcneill G, Creamer D, Walsh S. Contrast media and cutaneous reactions. Part 1. Immediate hypersensitivity reactions to contrast media and gadolinium deposition. Clin Exp Dermatol 2019;44:839-43. [DOI: 10.1111/ced.13990] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
680 Martino C, Costa C, Roccheri MC, Koop D, Scudiero R, Byrne M. Gadolinium perturbs expression of skeletogenic genes, calcium uptake and larval development in phylogenetically distant sea urchin species. Aquatic Toxicology 2018;194:57-66. [DOI: 10.1016/j.aquatox.2017.11.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
681 Liang X, Yeh CH. Editorial for "Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate meglumine and Gadobutrol to rats". J Magn Reson Imaging 2021. [PMID: 34046961 DOI: 10.1002/jmri.27749] [Reference Citation Analysis]
682 Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol. 2008;5:23-28. [PMID: 18180005 DOI: 10.1016/j.jacr.2007.08.013] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
683 Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009;30:1249-58. [PMID: 19938037 DOI: 10.1002/jmri.21967] [Cited by in Crossref: 117] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]
684 Bode A, Caroli A, Huberts W, Planken N, Antiga L, Bosboom M, Remuzzi A, Tordoir J. Clinical Study Protocol for the ARCH Project Computational Modeling for Improvement of Outcome after Vascular Access Creation. J Vasc Access 2011;12:369-76. [DOI: 10.5301/jva.2011.8382] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
685 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
686 Chang P, Saddleton E, Laumann AE, Schmitz B, West DP, Belknap SM, Parthasarathy S, Edwards BJ, McKoy JM, Miller FH. Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function. Acad Radiol 2012;19:1181-5. [PMID: 22831822 DOI: 10.1016/j.acra.2012.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
687 Steen H, Schwenger V. Good MRI images: to Gad or not to Gad? Pediatr Nephrol 2007;22:1239-42. [PMID: 17574478 DOI: 10.1007/s00467-007-0509-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
688 McDonald ES, Hammersley JA, Chou SH, Rahbar H, Scheel JR, Lee CI, Liu CL, Lehman CD, Partridge SC. Performance of DWI as a Rapid Unenhanced Technique for Detecting Mammographically Occult Breast Cancer in Elevated-Risk Women With Dense Breasts. AJR Am J Roentgenol 2016;207:205-16. [PMID: 27077731 DOI: 10.2214/AJR.15.15873] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 8.4] [Reference Citation Analysis]
689 Perazella MA, Rodby RA. Editorial: Gadolinium Use in Patients with Kidney Disease: A Cause for Concern: GADOLINIUM USE IN PATIENTS WITH KIDNEY DISEASE. Seminars in Dialysis 2007;20:179-85. [DOI: 10.1111/j.1525-139x.2007.00269.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
690 Jang B, Kwon H, Katila P, Lee SJ, Lee H. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. Advanced Drug Delivery Reviews 2016;98:113-33. [DOI: 10.1016/j.addr.2015.10.023] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 11.6] [Reference Citation Analysis]
691 Tan ET, Huston J 3rd, Campeau NG, Riederer SJ. Fast inversion recovery magnetic resonance angiography of the intracranial arteries. Magn Reson Med 2010;63:1648-58. [PMID: 20512868 DOI: 10.1002/mrm.22456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
692 Telgmann L, Holtkamp M, Künnemeyer J, Gelhard C, Hartmann M, Klose A, Sperling M, Karst U. Simple and rapid quantification of gadolinium in urine and blood plasma samples by means of total reflection X-ray fluorescence (TXRF). Metallomics 2011;3:1035. [DOI: 10.1039/c1mt00054c] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
693 Soares BP, Lequin MH, Huisman TA. Safety of Contrast Material Use in Children. Magnetic Resonance Imaging Clinics of North America 2017;25:779-85. [DOI: 10.1016/j.mric.2017.06.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
694 Mithal LB, Patel PS, Mithal D, Palac HL, Rozenfeld MN. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. Pediatr Radiol 2017;47:657-64. [PMID: 28283727 DOI: 10.1007/s00247-017-3810-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
695 Ranga A, Agarwal Y, Garg KJ. Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function. Indian J Radiol Imaging 2017;27:141-7. [PMID: 28744073 DOI: 10.4103/0971-3026.209212] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21]